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ABSTRACT 
Biochemical and phannacological studies of the metabolism of 
dynorphin 1-8 
Keywords: Spinal cord, opioid peptides, dynorphin 1-8, [Leulenkephalin, opioid 
receptors, metabolism, peptidase. 
The metabolism of the opioid peptide [3Hldynorphin 1-8 by slices of central 
nervous system (c.n.s.) and peripheral tissues, from the rat and guinea-pig has 
been studied. Rat spinal cord rapidly degraded [3H]dynorphin 1-8, the N-terminal 
tyrosine residue being most susceptible to hydrolysis and therefore forming the 
major metabolite. Pretreatment of the metabolizing tissue with a standard cocktail of 
enzyme inhibitors decreased the degradation of [3Hldynorphin 1-8 at both the N-
and C-termini. However, inclusion of this enzyme inhibitor cocktail revealed the 
activity of a further enzyme, an endopeptidase, capable of cleaving the leucine5-
arginine6 bond within the octapeptide liberating the opioid pentapeptide 
[Leulenkephalin. This pattern of metabolism was observed across all rat brain 
regions and periphery. 
The endopeptidase so revealed was resistant to serine protease inhibitors and metal 
chelating agents, but was inhibited potently by thiol protease inhibitors and two 
active site directed inhibitors of the endopeptidase E.C. 3.4.24.15. A variety of 
other opioid peptides were able to act as competitive substrates, the optimum 
substrate length falling between 8 and 13 amino acid residues. 
In addition, the effect of this metabolism on the receptor selectivity of dynorphin 1-
8 was assessed using the guinea-pig myenteric plexus longitudinal muscle 
preparation. A range of opioid antagonists were used to construct Schild plots 
against dynorphin 1-8, under a variety of inhibitory conditions, in order to derive 
Ke values which were then compared to values obtained using standard agonists at 
kappa and mu opioid receptors. 
Using the nonselective antagonist naloxone, dynorphin 1-8, in the absence of 
inhibitors afforded a Ke within the range associated with an interaction with a kappa 
receptor population. Addition of the standard cocktail of inhibitors lowered the Ke 
to a value indicative of an action at a mu receptor population. Metabolism studies 
using the guinea-pig myenteric plexus longitudinal muscle as metabolizing tissue 
revealed the production of [3H][Leulenkephalin from [3Hldynorphin 1-8 in the 
presence of the cocktail of enzyme inhibitors. The mu Ke value thus obtained 
would appear to be the result of the conversion of the kappa preferring octapeptide 
to the mu preferring pentapeptide (Leulenkephalin. In Schild plots constructed 
using dynorphin 1-8 stabilised with the standard inhibitory cocktail and an enzyme 
inhibitor capable of blocking the endopeptidase (E.C. 3.4.24.15) activity, the Ke 
rose significantly to a value comparable to that displayed by the most selective 
kappa agonists currently available. 
An ontogenic study revealed rat c.n.s. was able to liberate [3H](Leu ]enkephalinfrom 
rH]dynorphin I -8 as early as post-natal day I. In addition degradation of the N-termini was also 
evidenteveninthepresenceoftheaminopeptidaseinhibitorbestatin(IOIlM). Thepeakin 
enzyme activitythatliberateesthe pentapeptidefrom dynorphin I -8is seenin all C.n. s. areas 
tested at around postnatal day 10. Tbis correspond s to th e appearence of the flfSt detectable ~~II 
levels of delta opioid receptorsin the rat c.n. s. ~ ~ 
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CHAPTER 1 
Introduction 
GENERAL 
Morphine has been used for many centuries to relieve pain. However very 
little progress was made to answer the question of how morphine was able 
to elicit pain relief, or its myriad of other pharmacological effects, until the 
early 1970's. 
In 1973 several groups, working independently, published results that 
revealed a saturable binding site for radiolabelled morphine derivatives in 
central nervous system tissue [125,142,153,169]. The specific binding of 
[3Hl -opiates to this site was highest in the synaptosomal fraction of brain 
homogenates and was decreased in the presence of proteolytic enzymes 
[125, 126, 142] indicating the binding site was on, or near to, nerve terminals 
and was proteinaceous in nature. The binding site was also found to be 
sensitive to temperature, pH and sulphydryl reagents. The ability of 
agonists, but not antagonists, to displace bound tritiated antagonist was 
decreased in the presence of cations, especially sodium [125, 126, 142]. In 
addition the opiate Ievorphanol was able to displace rHldihydromorphine 
bound to membranes of rat brain whereas its stereoisomer dextrorphan was 
not [170]. This stereoselective binding provided further strong evidence to 
support the existence of an opioid specific receptor within the nervous 
system and this evidence gave impetus to the search for an endogenous 
ligand for this newly discovered receptor. 
In 1975 John Hughes [77] working with Hans Kosterlitz in Aberdeen was 
successful in isolating a substance from porcine brain that mimicked the 
action of morphine in in vitro pharmacological ~ssays, in particular the 
electrically stimulated mouse vas-deferens. Earlier work had shown this 
tissue was responsive to opiates which depressed electrically stimulated 
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contractions in a naloxone reversible manner, a fmding later extended to 
incll!de the rat, rabbit and hamster vas deferens Naloxone, a pure opiate 
selective antagonist, is able to completely reverse the actions of morphine. 
Consequently antagonism by naloxone is the reference point for defmition 
of all opioid activity. The "morphine-like factor", isolated by Hughes and 
Kosterlitz, could also displace the opioid antagonist pm-naloxone bound to 
rat brain membranes and thus displayed an affmity for the receptor 
recognised by this tritiated ligand [121]. 
The "morphine-like factor" had the properties of a peptide as both its ability 
to displace rH]-naloxone from specific binding sites in rat brain 
homogenates and its potency in phannacological assays decreased after 
treatment with proteolytic enzymes [79, 121]. Indeed towards the end of 
1975 the structure of the "morphine-like factor" was elucidated and found to 
consist of two related pentapeptides [79,80]. These two peptides were 
named leucine-enkephalin and methionine-enkephalin [Fig. 1.1] (hereafter 
written [Leu]enkephalin and [Met]enkephalin respectively). As can be seen 
from Figure 1.1 the two peptides differ only in their C-terminal amino-acid 
residue, from which their respective names are derived. Peptides such as 
[Leu] and [Met]enkephalin and many more recently discovered peptides are 
known as opioid peptides. 
To differentiate the terms opiate and opioid the following definition will be 
used throughout this thesis. The term opiate describes any molecule that is 
derived directly from an alkaloid present in the opium poppy and is active at 
opioid receptors. Whereas the term opioid denotes any molecule active at 
opioid receptors that is not derived from the opium poppy. 
2 
Tyr -- Gly -- Gly --
H}-~H 
-N "-< 
Leucine 
H)-OH 
-N ~ 
SMe 
Methionine 
Figure 1.1 ; The Enkephalins 
Phe - R 
Leucine- enkephalin 
( [Leu Jenkephalin ) 
Methionine - enkephalin 
( [Met Jenkephalin ) 
At approximately the same time indications that the receptor to which 
opioids and opiates specifically bound was not of a single type were 
suggested. A decade earlier Martin and co-workers [lOO, 101, 104] observed 
that two synthetic opitlid antagonists nalorphine and cyclazocine, in addition 
to their antagonist effects, produced analgesia and euphoric effects in man. 
However the subjective effects produced by the chronic administration of 
cylazocine or nalorphine were qualitatively different to those produced by 
morphine. Futhermore cyclazocine was unable to suppress abstinence 
syndrome in subjects physically dependent on morphine. This evidence lead 
Martin to propose that morphine and nalorphine were acting via different 
receptors and consequently that the opioid receptor population was not 
homogeneous. Following further work in the mid 1970's Martin and 
colleagues proposed three distinct classes of opioid receptor based on the 
observed pharmacological properties of different opiates in the non-
dependent and morphine-dependent chronic spinal dog preparation [47, 102]. 
In this preparation Martin observed differences in behaviour caused by the 
intravenous administration of morphine, ketocylazocine and N-
a1lylnormetazocine (SKF-I0,047). All three drugs are agonists as their 
actions can be antagonised by a pure antagonist, in this case, naltrexone. 
Ketocylazocine failed to suppress abstinence syndrome in morphine-
dependent animals. Whereas buprenorphine, a partial agonist at the 
morphine receptor, both precipitated and suppressed abstinence in the 
morphine dependent dog. In addition morphine and cylazocine displayed 
differences in their sensitivity to the opioid antagonists naloxone and 
naltrexone. Both antagonists are 20 to 6 times less potent in precipitating 
abstinence in cyclazocine dependent dogs [103]. From these observations 
Martin described three receptor types namely the mu receptor, the kappa 
receptor and the sigma receptor at which morphine, ketocyc1azocine and N-
aIIylnormetawcine respectively were the putative Iigands. 
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The presence of mu and kappa receptors was generally confmned using 
isolated tissue preparations, in particular the mouse vas-deferens and the 
myenteric plexus longitudinal muscle of the guinea-pig ileum [82]. However 
these and other investigations produced results that were difficult to explain 
in terms of the three opioid receptors, namely mu, kappa and sigma. For 
example [Met]enkephalin was 20 times more potent than normorphine at 
inhibiting the electrically invoked contractions of the mouse vas-deferens 
whereas the two drugs were equipotent in the guinea-pig ileum assay [80]. 
Additionally [Met]enkephalin was at least 3 times more potent than 
morphine in displacing [3H]naloxone bound to guinea-pig brain 
homogenate [80]. Futhermore the rank order of potency of a variety of 
opioid agonists at inhibiting the electrically evoked contractions in the 
mouse vas-deferens and the guinea-pig myenteric plexus longitudinal 
muscle were widely different [96]. In the mouse vas-deferens the relative 
potency, referred to norrnorphine as standard, of the Jigands for the kappa 
receptor, namely the ketocyc1azocines, is only 25% of that found in the 
guinea-pig ileum [82]. Indeed in both preparations the ketocylazocines 
require 3-6 times more naloxone or naltrexone to reverse their agonist action 
compared with the dose of antagonist necessary to reverse the action of 
morphine [82]. These varied observations were reinforced by the actions of 
the opioid peptides on these two preparations. Beta-endorphin, a 31 amino 
acid opioid peptide, discovered following the isolation of the enkephalins, 
as a C-terminal fragment of beta-LPH, is the only peptide to display similar 
potency in both the mouse vas-deferens and the guinea-pig ileum. Both 
[Met] and [Leu]enkephalin are more potent in the mouse vas-deferens than 
in the guinea-pig ileum [96]. These discrepancies are borne out by the action 
of antagonists. In the guinea-pig ileum the enkephalins and normorphine are 
antagonised equally well by naloxone [96]. Whilst in the mouse vas-
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deferens 10 times more naloxone is required for the antagonism of the 
pentapeptides than for that of normorphine. In addition the agonist activity 
of opioids in the guinea-pig ileum was better correlated to their inhibition of 
rH]naloxone binding than to inhibition of [3H][Leu]enkephalin binding. In 
contrast, opioid agonist activity in the mouse vas-deferens is not correlated 
to inhibition of rH]naloxone binding but has a similarity to the pattern of 
inhibition of rH][Leu]enkephalin binding [96]. 
All the above evidence supports the presence of a further receptor type. 
Kosterlitz and colleagues therefore proposed the existence of a receptor 
type, that they named the delta receptor, which displayed a high affinity for 
[Leu] and [Met]enkephalin [95]. Subsequent studies have shown that the 
actions of agonists at the sigma receptor are not reversed by naloxone [151]. 
It is therefore, common practice to refer to only three types of opioid 
receptor, namely the kappa-receptor, the mu-receptor and the delta-receptor. 
[Met] and [Leu]enkephalin and beta-endorphin are not the only endogenous 
pep tides capable of acting at opioid receptors. By 1982 a further family of 
opioid peptides had been isolated, namely the dynorphins, and many 
products related to [Leu] and [Met]enkephalin had been identified 
[Table 1.1]. These form three distinct families of pep tides and are classified 
according to the prohormones from which they are derived. These 
prohormones, once fully sequenced, were named proopiomelanocortin 
(POMC), proenkephalin A and prodynorphin (also termed proenkephaIin 
B). 
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Peptide 
Proopiomelanocortin 
products 
~-endorphin 
C'-fragment 
'Y-endorphin 
a-endorphin 
Proenkephalin A 
products 
[Met]enkephalin 
[Met]enkephalyl-Arg6 
[Met]enkephalyl-Lys6 
[Met]enkephalyl-Arg6-Phe7 
[Met]enkephalyl-Arg6-Arg7 
[Met]enkephalyl-Arg6-Gly7-Leu8 
[Leu]enkephalin 
PeptideE 
Table 1.1 Opioid Peptides 
Alternative Name 
C-fragment, ~-LPH61-91 
o-endorphin, ~-LPH61-87 
~-LPH61-77 
~-LPH61-76 
Methionine-enkephalin, Met-enk 
pro-methionine-enkephalin 
MEAP,MERF 
MERGL 
Leucine-enkephalin, Leu-enk 
Amino Acid Sequencnce 
Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-
Lys-Ser-Gl u-Lys-Ser-Gln-Thr-Pro-Leu-
Val-76Thr77Leu-Phe-Lys-Asn-Ala-Ile-
Ile-Lys-Asn-Ala-87His-Lys-Lys-Gly-
91Gln 
Tyr-Gly-Gly-Phe-Met 
............................ -Arg 
............................ -Lys 
............................ -Arg-Phe 
............................ -Arg-Arg 
............................. -Arg-Gly-Leu 
Tyr-Gly-Gly-Phe-Leu 
Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-Gly-Arg-
Pro-12Glu-Trp-Trp-Met-Asp-Tyr-Gln-Lys-
20 Arg-Tyr-22Gly-Gly-Phe-25Leu 
Peptide 
Proenkephalin A 
products (cont) 
BAM-12P 
BAM-20P 
BAM-22P 
Metorphamide 
Peptide F 
Prodynorphin 
products 
[Leulenkephalin 
~-neo-endorphin 
a-neo-endorphin 
Dynorphin 32 
Dynorphin A 
Dynorphin B 
[Leulenkephalin-Arg6 
[Leulenkephalin-Arg6-Arg7 
Dynorphin 1-8 
-
Table 1.1 Opioid Peptides (cont) 
Alternative Name 
Adrenorphin 
Dynorphin 1-17 
Rimorphin 
Dynorphin 1-6 
Dynorphin 1-7 
PH-8P 
Taken with kind permission from Kitchen. I. 1984. Proa Neurobiol .. 22345-358 
Amino Acid Sequence 
Peptide E (1-12) 
Peptide E (1-20) 
Peptide E (1-22) 
Peptide E (1-8) NH2 
Tyr-Gly-Gly-Phe-Met-Lys-Lys-Met-Asp-Glu-
Leu-Tyr-Pro-Leu-Glu-V al-Glu-Glu-Glu-Ala-
Asn-Gly-Gly-Leu-Val-Leu-Gly-Lys-Arg-Tyr-
Gly-Gly-Phe-Met 
Tyr-Gly-Gly-Phe-Leu 
............................ -Arg-Lys-Tyr-Pro 
............................ -Arg-Lys-Tyr-Pro-Lys 
lTyr-Gly-Gly-Phe-Leu-Arg-Arg-8Ile-Arg-pro-
Lys-Leu- 13Lys-Trp-Asp-Asn-17Gln-Lys-Arg-
20Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-
Lys-Val-VaP2Thr 
Dynorphin 32 sequence (17) 
Dynorphin 32 sequence (20-32) 
Tyr-Gly-Gly-Phe-Leu -Arg 
Tyr-Gly-Gly-Phe-Leu-Arg-Arg 
Tyr-G ly-Gly-Phe-Leu-Arg-Arg-lIe 
2 3 1 1 4 3 1 
'Y-M 
CLIP 
LACTH~ 
4 1 
p-MSH 
'Y-LPH-I 
4 
CDOH 
end 1-27 
p-endorphin ----I 
I Methionine EnkephaJin p-LPH --------1 
Figure 1.2: Schematic representation of proopioimelanocortin (POMC) 
1 = lysine - arginine 
2 = arginine -lysine 
3 = arginine - arginine 
4 = lysine - lysine 
MSH = melanocyte stimulating hormone 
ACTH = adrenocorticotropic hormone 
CLIP = corticotropin like intemlec1iate lobe peptide 
LPH = li potropin 
PROOPlOMELANOCORTIN 
Proopiomelanocortin (POMC) is the precursor for the opioid peptide beta-
endorphin, and also adrenocorticotropic hormone (ACIH) and various 
melanocyte stimulating hormone (MSH) containing pep tides [Fig. 1.2; 
Table 1.1]. All metabolic products ofPOMC are bound by pairs of basic 
amino acids which are common sites for peptidase attack [lll]. 
The major source of POMC is the pituitary gland and both anterior and 
intermediate lobes contain beta-endorphin. The intermediate lobe produces a 
greater amount of post-translational modification of the released hormones, 
such as alpha-N-acetylation leading to the loss of opioid activity and 
shortening of the C-terminus [73]. The processing of POMC in brain 
parallels that found in the intermediate lobe. Although POMC contains one 
sequence of [Met]enkephalin, located at the N-tenninal of beta-endorphin, it 
is not the primary source of [Met]enkephalin found in central nervous 
system (c.n.s.) tissue [165]. POMC products are not found in adult spinal 
cord, although beta-endorphin is present in the embryonic spinal cord of the 
rat [61]. 
In radioligand binding experiments beta-endorphin shows a slight selectivity 
for mu over delta-receptors with negligible affinity for the kappa-receptor 
[88]. However in a variety of isolated tissue studies beta-endorphin has not 
been seen to display selectivity between the mu and delta-receptor [73]. In 
the rat vas-deferens beta-endorphin appears to act via a receptor that is not 
ofthe mu, delta or kappa type [141]. Although this has been termed the 
epsilon receptor its nature remains to be confmned. Indeed its actual 
existence is still a matter of debate as some have suggested a low receptor 
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reserve is responsible for the low potency of various agonists in this tissue 
and that the epsilon receptor is in fact a mu receptor [49,145]. 
Beta-endorphin is resistant to enzyrnatic attack, a feature that increases its 
potency in phannacological assays [107]. Consequently 
intracerebroventricular (i.c.v.) injections of beta-endorphin produce 
profound analgesia [74]. Furthermore beta-endorphin administered i.c.v. 
releases [Met]enkephalin from the spinal cord of anaesthetised rats [159], 
which may suggest that beta-endorphin elicits its analgesic effect by 
stimulating a descending opioid pathway [149]. However caution should be 
used when interpreting results as Le.v. injections of beta-endorphin also 
cause profound catalepsy. In addition to analgesia, beta-endorphin affects 
several hormonal systems, being, for example, involved in the release of 
prolactin from the pituitary [72]. Beta-endorphin therefore serves a variety 
of roles, many of which tend to be neurohormonal rather than those of a 
classical neurotransmitter. 
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PROENKEPHALIN A 
Once sequenced, proenkephalin A was seen to contain four copies of 
[MetJenkephalin, one copy of [LeuJenkephalin, a single copy of 
[MetJenkephalyl-Arg6-Phe7 and one copy of [MetJenkephalyl-Arg6_GIy7-
Leus, each bound by basic pairs of amino acids [Fig. 1.3 J [5, 113J. 
However several other extended forms of [MetJenkephaIin have been 
isolated, for example the BAM (Bovine Adrenal Medullary) peptides 
purified from bovine adrenal medulla [Table 1.1J. 
The processing products of proenkephaIin A are found throughout the 
brain, especially in areas associated with nociception, for example the 
periaquaductal gray and basal ganglia [39J. The smaller fragments namely, 
[MetJenkephaIin, [MetJenkephalyl-Arg6-Phe7, [MetJenkephalyl-Arg6_Gly7-
Leus and [LeuJenkephaIin are all found in the dorsal horn of the spinal cord, 
especially in lamina I (marginal zone), lamina II (the substantia gelatinosa) 
and lamina V of Rexed [50, 83J. In general the processing in brain and spinal 
cord appears more complete than that in the adrenal medulla [160J. 
The various processing products of proenkephaIin A display a broad 
spectrum of opioid receptor selectivity. [MetJenkephaIin and 
[LeuJenkephalin display a 10 and 17 fold preference respectively for the 
delta receptor over the mu receptor, but do act as agonists at the mu 
receptor. However neither peptide is likely to interact with the kappa 
receptor [123, 174J. [MetJenkephalyl-Arg6-Gly7_Leu8 is non-selective 
between mu and delta and displays some kappa affinity. The ability of this 
peptide and [MetJenkephalyl-Arg6_Phe7 to act as agonists at kappa 
receptors is illustrated in isolated tissue experiments. These peptides are able 
to inhibit the electrically evoked contractions of the isolated vas-deferens of 
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the rabbit [75] a tissue that contains an homogenous kappa receptor 
population [115, 130]. However, the amidated peptide [Met]enkephalyl-
Arg6-Arg 7 -Va18-NH2 is the only member of the shorter processed products 
that shows high affinity for the kappa receptor [88]. More extended forms of 
[Met]enkephaIin do display an increased affinity for the kappa receptor. 
Thus both BAM-12P and BAM-22P are especially active in the rabbit 
isolated vas-deferens assay [75]. Both peptides also interact with the mu 
receptor as illustrated by their effectiveness in the rat vas-deferens and the 
guinea-pig myenteric plexus longitudinal muscle preparations [75]. Though 
the potency of BAM-12P is relatively Iow in the guinea-pig myenteric 
plexus longitudinal muscle preparation, this however is an indication of its 
susceptibility to enzymatic degradation causing an apparent lack of potency 
in this particular assay system [17,73]. 
The longer pep tides, E and F are related only in so much as they both 
contain enkephalin sequences at their N- and C-termini. Peptide E contains 
one [Met]enkephalin sequence at its N-terminal and one [Leu]enkephaJin 
sequence at its C-terminal, and displays a non-selective profile in isolated 
tissue assays, acting at both mu and kappa receptors [73]. Peptide F 
contains two [Met]enkephalin sequences, one at each terminal, and has 
negligible activity in the gninea-pig myenteric plexus longitudinal muscle 
preparation, mouse vas-deferens and rabbit vas-deferens hioassay systems. 
This lack of activity cannot be attributed to enzymatic degradation as the 
potency of peptide F is not substantially increased by the addition of 
peptidase inhibitors to the assay systems. Peptide F is, however, active in 
the rat vas-deferens assay, this coupled with its low affinity in the guinea-
pig myenteric plexus longitudinal muscle preparation may indicate an ability 
to act at the proposed non-mu, non-delta (epsilon) receptor in the rat vas-
deferens [73]. 
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The involvement of the mu opioid receptor in supraspinal analgesia is well 
documented [171]. Thus all the proenkephalin A products that display 
affinity and efficacy at the mu receptor have the potential to elicit analgesia at 
a supraspinal level. Peptides E and BAM-22P induce analgesia when 
injected intracerebroventricularly into mice [74]. However intraventricular 
injection of [Leu] or [Met]enkephalin in mice cause only weak inhibitory 
effects in behavioural analgesic tests. This is probably due to their rapid 
metabolism since the half life in rat plasma of both peptides is less than 2.5 
minutes [57]. Intraventricular injections of the enzyme inhibitor thiorphan, 
which is able to prevent the peptidase activity responsible for the hydrolysis 
of the Gly4-Phe5 bond within opioid peptides, both increases the analgesic 
potency of exogenously applied opioid peptides and when given alone 
produces a naloxone reversible analgesia, suggesting a stabilization of 
endogenous peptides [131a]. 
All three types of opioid receptor have been found in spinal cord [155] and 
when occupied by appropriate opioid agonists analgesia can result [102, 
171]. This is difficult to demonstrate following intrathecal injections of the 
shorter proenkephalin A products as these are again fraught with the 
problems of enzymatic inactivation. However, the intrathecal injection of the 
pentapeptide analogue namely [o-Ala2,D-Leu5]enkephalin, synthesized to be 
resistant to enzymatic attack, has been shown to elicit naloxone reversible 
analgesia at the spinal level in hot plate tests carried out in rats as has the 
more selective delta ligand [D-Pen2,o-Pen5]enkephalin and the mu ligand 
[D-Ala2,MePhe4, Glyol5]enkephalin [40, 135, 136, 158]. 
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Prodynorphin, the last of the opioid prohonnones to be sequenced [87], 
contains three copies of [Leu]enkephalin each flanked by basic amino acid 
pairs [Fig. 1.4]. Processing of this prohonnone yields extended fonns of 
the three [Leu]enkephalin copies. Two of these namely, beta-neo-endorphin 
and dynorphin 1-17 are both contained within pairs of basic amino acids. 
However cleavage at single arginine residues also occurs yielding alpha-
neo-endorphin; dynorphin B, from cleavage of the threoninel3-argininel4 
bond ofleumorphin; anddynorphin 1-8 via the hydrolysis of the 
isoleucine8-arginine9 bond within the dynorphin 1-17 sequence. Dynorphin 
1-13 is liberated via the cleavage of the leucine13_lysineI4 bond within 
dynorphin 1-17. As with proenkephalin A the smaller processing products 
of prodynorphin appear to be most abundant in brain tissue and spinal cord 
[138]. However the processing is not homologous throughout the c.n.S. and 
regional variations do occur. 
Dynorphin 1-8 is found throughout the brain, its concentration being 
especially high in the substantia nigra. In all brain areas alpha-neo-
endorphin is more abundant than beta-neo-endorphin [138], this is probably 
due to the higher rate of hydrolysis of the beta-neo-endorphin by certain 
endopeptidases (see below). Dynorphin B fonned via thiol protease activity 
from dynorphin B-29, is also widely distributed throughout the brain, the 
highest concentration being located in the substantia nigra [175, 178]. The 
posterior pituitary is rich in all prodynorphin products, whereas the anterior 
pituitary contains only one species of prodynorphin product, a 6000 Da 
high molecular weight species [138, 140]. Immunoreactive dynorphin is 
found in rat spinal cord, the dorsal horn containing the highest level, 
probably in short axoned neurons [14]. Dynorphin A and alpha-neo-
endorphin in human spinal cord are again located in the dorsal horn, 
especially in the substantia gelatinosa [128]. 
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Zamir and colleagues have also shown that [Leu]enkephalin in the 
substantia nigra is synthesized via a dynorphinergic pathway [176]. This 
same group had previously observed the concentrations of alpha- and beta-
neo-endorphin to be considerably higher than the concentrations of 
dynorphin A (plus its metabolic fragment dynorphin 1-8) or dynorphin B. 
This was especially striking in the substantia nigra, where the level of 
[Leu]enkephalin is more than twice that of [Met]enkephalyl-Arg6_Gly7-
Leu8, a peptide derived exclusively from the proenkephalin precursor where 
like [Leu]enkephalin it is found as a single copy [176]. These observations 
led to a further series of experiments designed to detenuine the source of 
[Leu ]enkephalin in the substantia nigra of rat brain. Unilateral lesions just 
rostral to the mesencephalon that transected descending fibres from the 
forebrain resulted in a marked depletion of nigral alpha-neo-endorphin, 
dynorphin Band [Leu]enkephalin but did not alter the levels of 
[Met]enkephalyl-Arg6-Gly7_Leu8• This suggested that [Met]enkephalyl-
Arg6-Gly7-Leu8 is not contained in descending inputs into the substantia 
nigra whereas the dynorphin related pep tides and [Leu]enkephalin must be 
in axons of neurons rostral to the substantia nigra. In a second set of 
animals the globus pallidus was lesioned from the caudate putamen resulting 
in a decrease in alpha-neo-endorphin, dynorphin Band [Leu]enkephalin in 
the ipsilateral substantia nigra without altering the level of [Met]enkephalyl-
Arg6-Gly7-Leu8• This lesion also resulted in a decrease in alpha-neo-
endorphin, [Leu]enkephalin and [Met]enkephalyl-Arg6-Gly7-Leu8 in the 
globus pallidus confinuing earlier observations of a proenkephalinergic 
striatopallidal pathway [31]. In addition these observations provide evidence 
for the existence of a dynorphinergic striatonigral and a striato (or cortico)-
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pallidal pathway. The most appropriate explanation for the parallel decreases 
in alpha-neo-endorphin, dynorphin Band [Leu]enkephalin whilst the level 
of [Met]enkephalyl-Arg6_Gly7_Leu8 remains unaltered is that in the 
striatonigral pathway [Leu]enkephalin is produced in dynorphinergic 
neurons [176]. The production of [Leu]enkephalin from a dynorpbinergic 
neuron may have important physiological implications, as it allows the 
neuron to produce both a kappa (dynorphin) and a delta ([Leu]enkephalin) 
ligand from the same precursor. This may occur by direct processing or 
could conceivably occur at a later stage via the hydrolysis of dynorphin A 
and thus provides a possible explanation of why the concentration of 
dynorphin B is higher than that of dynorphin A in most brain areas if the 
latter is converted to smaller fragments especially in the substantia nigra. 
In addition the co-localization of prodynorphin products is not uncommon. 
Immunohistochemical methods have shown alpha-neo-endorphin and 
dynorphin 1-17 staining in the same fibres in numerous areas of the rat 
brain including substantia nigra, hypothalamus, nucleus accumbens, 
hippocampus and medulla oblongata [166, 167]. There is also evidence to 
suggest that co-localization of proenkephalin A and prodynorphin derived 
peptides occurs in both brain and spinal cord [56, 167]. This is seen in the 
spinal cord of arthritic rats where neurons in Laminae IV and V stain for 
four opioid peptides namely [Met]enkephalyl-Arg6_Phe7, [Met]enkephalyl-
Arg6-Gly7-Leu8, dynorphin 1-17 and alpha-neo-endorphin [168]. 
All the fragments of prodynorphin greater than seven amino acids in length 
exhibit varying degrees of selectivity towards the kappa receptor, as 
illustrated by their ability to inhibit the electrically evoked contractions of the 
rabbit vas-deferens, a tissue known to contain exclusively kappa receptors 
[28,88]. Increasing the length of the peptide above seven amino acids 
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progressively increases their affinity for the kappa site up to dynorphin 1-13 
which has the highest affinity for the kappa receptor. However dynorphin 
1-13 also displays the highest relative affinities at all three opioid binding 
sites [28]. [LeuJenkephalin is the only prodynorphin product to show any 
appreciable selective affinity for the delta receptor. As peptide length 
decreases towards the pentapeptide an increase in the delta afflnity over 
kappa affinity is observed, the affinity towards the mu receptor is not 
affected to the same degree [28, 88J. 
The dynorphin peptides when injected into cerebral ventricles show a 
distinct lack of effect in analgesic tests [23, 58J though evidence exists to 
suggest that the dynorphins are able to elicit their analgesic effect via an 
activation of spinal opioid receptors. Thus dynorphin 1-17 induces 
profound analgesia in the tail flick test following i.c.v. administration [58J. 
However this effect is only partially reversed by intrathecal injections of 
naloxone and is completely unaffected by subcutaneous application of 
naloxone. Dynorphin B also increases tail flick latency, but again this effect 
is only partially reversed by naloxone [59J. Unfortunately neither of the 
above studies involved the assessment of motor function following the 
intrathecal injection of the dynorphin peptides. This is an important 
omission as Stevens and Yaksh [147] have shown that severe motor 
dysfunction occurs following the intrathecal injection of dynorphin 1-17 and 
1-13 at levels well below those used in the above analgesic tests. This effect 
appears to be non-opioid in nature as the motor dysfunction is not reversed 
by naloxone. In addition dynorphin 3-13, a peptide fragment inactive at 
opioid receptors, due to its lack of N-terminal tyrosine also induces motor 
dysfunction [22J. The shorter dynorphins 1-7, 1-8, 1-9 and 1-10 did not 
appear to impair motor function, however when co-administered with 
peptidase inhibitors these peptides also caused hindlimb dysfunction [94J. 
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Dynorphin 1-17 and 1-13 were ineffective at eliciting analgesia in the hot 
plate, tail flick and writhing tests when injected intrathecally at doses just 
below those shown to elicit impainnent of motor function [147]. None of the 
shorter dynorphin pep tides were able to elicit analgesia in any of the tests 
listed above. Similarly intrathecal application of the kappa preferring 
synthetic non-peptide agonist U50 488H (trans,3,4-dichloro-N-methyl-
N[2-(1-pyrrolidinyl)cyc1ohexyl]-benzeneacetarnide) which did not affect 
motor function was ineffective in the hot plate and tail flick tests. However 
this latter compound elicited a dose dependent inhibition of writhing that 
was naloxone reversible [147]. It is possible therefore to suggest that 
activation of kappa receptors by dynorphins is unlikely to cause motor 
dysfunction, but other actions have a powerful influence on motor output. 
The ability of the dynorphins, especially the shorter fragments, to elicit 
analgesia remains therefore open to question. In light of their possible 
metabolism by central nervous system tissue [28.48.173] it is difficult to 
ascertain whether the effects observed following the administration of 
dynorphin peptides are due to the peptide or unknown metabolic products. 
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OP/oJD PEPTlDES IN THE SPINAL CORD 
The dorsal horn of the spinal cord is an important site for the control and 
modulation of nociceptive information [41,172]. High levels of opioid 
receptors are found in the dorsal horn of the spinal cord and are distributed 
throughout the rostral-caudal axis [6]. The ratio of kappa/mu/deJta receptors 
is approximately the same along the rostral-caudal axis with kappa binding 
accounting for the majority of bound radioactivity [155]. Autoradiographic 
studies have shown opiate receptors to be concentrated in specific laminae 
within the dorsal horn of the spinal cord. The superficial layers namely 
laminae I and IT (the substantia gelatinosa) [Fig. 1.5] are especially rich in 
opioid binding sites [6, 143]. The presence of opioid receptors within the 
superficial layers of the dorsal horn is indicative of their importance in the 
modulation of nociceptive inputs into the spinal cord. The substantia 
gelatinosa receives inputs from and sends inputs to the periaquiductal grey 
and adjacent reticular formation nuclei within the brainstem all of which are 
major nociceptive processing centres [41,54,172]. Dorsal root section or 
neonatal capsaicin, which causes a selective destruction of unmyelinated and 
fine myelinated primary afferent fibres, significantly reduces opioid receptor 
density in the dorsal horn [7,42, 110, 112] suggesting a proportion of opioid 
receptors within the dorsal horn are located on presynaptic primary afferent 
nerve terminals. 
The dorsal-ventral distribution of opioid receptors is broadly paralleled by 
the distribution of opioid peptides. The concentrations of proenkephalin A 
and prodynorphin products are higher in the dorsal rather then ventral horn 
of the spinal cord throughout the rostral-caudal axis [128, 175]. Along the 
rostral-caudal axis the levels of prodynorphin derived peptides in the ventral 
portion of the spinal cord are low, however [Met]enkephalin levels in the 
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ventral horn can reach 60% of those found in the dorsal horn [128]. Unlike 
the dorsal-ventral distribution, the levels of opioid peptides along the ro~l­
caudal axis of the spinal cord do not parallel the homogenous distribution of 
opioid binding sites. The majority of studies have revealed the highest levels 
of immunoreactive peptide to be located in the sacral region of the cord with 
the concentration decreasing in a rostral direction. For example the level of 
[Met]enkephalyl-Arg6_Phe7 in the sacral region of the rat spinal cord is over 
twice that found in the cervical region [97]. This distribution pattern is seen 
more acutely in the dorsal horn where the level of sacral [Met]enkephalyl-
Arg6-Gly7-Leu8 is three times that found in the cervical spinal cord [83]. 
However discrepancies are reported, Zamir and colleagues have described 
cervical levels of immunoreactive dynorphin B that are over twice as high as 
those found in lumbar spinal cord [175]. In human spinal cord the 
distribution of the prodynorphin products dynorphin 1-17 and alpha-
neoendorphin and the proenkephalin A product [Met]enkephalin closely 
parallels that of [Met]enkephalyl-Arg6-Phe7 and [Met]enkephalyl-Arg6-
Gly7-Leu8 [128] derived from proenkephalin A. 
Taken together these results show a distribution of prodynorphin and 
proenkephalin A products along the rostral-caudal axis of the spinal cord. 
Prodynorphin products appear to be concentrated within the dorsal horn and 
are especially high in the substantia gelatinosa [128, 175]. Proenkephalin A 
products are also high in the dorsal horn but the distribution of [Met] and 
[Leu]enkephalin is not as precise and both pentapeptides are also found in 
substantial concentrations in the ventral horn [50, 175]. It would appear 
therefore that both prodynorphin and proenkephalin A products are found in 
areas of the spinal cord where they are able to modulate sensory information 
[70]. The role of proenkephalin A products located in the ventral spinal 
cord, where they have been shown to be present in serotonergic neurones 
making synaptic contact with alpha-motoneurones, may be able to modulate 
spinal motor function [71]. 
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Figure 1.5 : Positions of cytoarchitectonic laminae of Rexed in the grey matter of 
the human spinal cord at 3 levels, the cervical enlargement, the thoracic region and 
the lumbosacral enlargement. Note: lamina VI is only present in limb enlargemants. 
METABOLISM OF OPIOID PEPTIDES 
It became apparent shortly after the isolation of [Met) and [Leu)enkephalin 
that the pentapeptides were susceptible to enzymatic attack [10,57,77,91, 
173). Since an intact tyrosine residue at the N-terminus of an opioid peptide 
is necessary for binding to opioid receptors [95) cleavage of the tyrosineL 
glycine2 bond by aminopeptidases is, therefore, especially important 
Deactivation of both pentapeptides and the dynorphins has been 
demonstrated to occur via cleavage of this bond [36,48,57) in a variety of 
tissues, including rat and mouse brain homogenates [36,48,99) and guinea-
pig ileum [78). 
Cleavage of the TyrLGly2 bond is not confined to a single aminopeptidase. 
A variety of aminopeptidases, varying in their susceptibility to a broad 
spectrum of inhibitors, appear to be responsible for the release of the N-
terminal tyrosine. However most are metalloenzymes and are inhibited by a 
wide variety of chelating agents [66). Much ofthe enzyme activity is 
contained within the soluble fraction of brain homogenates and is found 
throughout the brain rather than in discrete areas specifically associated with 
opioid peptide content [137). An exception to this rule is a membrane bound 
aminopeptidase, designated aminopeptidase M H, that has been purified 
from rat brain. This enzyme displays a regional distribution parallel to that 
displayed by opioid receptors [68) and is inhibited by bestatin but is 
distinguished from other membrane aminopeptidases by its sensitivity to 
puromycin [65,68]. 
Immunohistochemical studies have revealed a further aminopeptidase, 
namely aminopeptidase M, which unlike aminopeptidase M H is insensitive 
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to puromycin and is located on the walls of cerebral blood vessels [69].and 
would therefore be unable to hydrolyse synaptic enkephalin but could 
maintain a concentration gradient between synaptic and interstitial 
enkephalin levels thereby ensuring efficient diffusion of enkephalin from the 
synapse. In addition Hui and co-workers have isolated a opioid receptor 
associated aminopeptidase from rat brain that is able to hydrolyse the 
pentapeptides [81], however peptide binding to the opioid receptor is not 
coupled to biodegradation [109]. 
The importance of aminopeptidase M IT in enkephalin metabolism is 
questionable. When administered i.c.v. into mice the aminopeptidase M II 
inhibitor puromycin failed to prevent the hydrolysis of co-administered 
[3H][Leu]enkephalin. In addition the latency time in the hot plate test was 
unaffected by puromycin administered alone i.c.v. indicating the inability of 
puromycin to prevent the hydrolysis of endogenous enkephalin. In contrast 
the general aminopeptidase inhibitor bestatin did increase the latency time 
when administered i.c.v. [20]. However in another study puromycin 
produced a naloxone reversible, dose related analgesia in rats accompanied 
by an increase in striatal enkephalin levels [64]. 
In addition to the aminopeptidases cleaving the N-terminal tyrosine residue, 
a dipeptidylaminopeptidase, releasing TyrLGly2 fragments is also found in 
brain [24,53]. This enzyme is also a metallopeptidase [148] thus far found to 
be present in brain tissue of pig [24], monkey [62], calf and rat [161]. The 
three enzymes are probably closely related as they display the same type of 
substrate specificity, namely the requirement of three hydrophobic amino 
acid residues, as the minimal sequence to be cleaved [24]. However an 
active site directed inhibitor of the dipeptidylaminopeptidase purified from 
porcine brain, administered with [Lell]enkephalin into the cerebral ventricles 
of mice, failed to affect the jump latency time in the hot plate test as 
compared with [Leu]enkephalin given alone [24]. It would appear therefore 
that the dipeptidylaminopeptidase does not play a major role in enkephalin 
metabolism at supraspinal levels. 
Degradative attack of the C-tenrunus of the pentapeptides and dynorphins is 
carried out by a dipeptidy1carboxypeptidase. As early as 1978 cleavage of 
the Gly3-Phe4 bond within [Leu]enkephalin, by an enzyme associated with 
the membrane fraction of mouse brain was observed [98]. This enzyme 
appeared to have a higher specificity towards the enkephalin molecule than 
that displayed by any of the aminopeptidases. Neurochemical and 
neuropharmacological studies suggest a close relationship between the 
dipeptidylcarboxypeptidase and the opioid systems within the c.n.s. [98]. 
Indeed, an association between opioid pathways and the high affinity 
dipeptidyJcarboxypeptidase is probable considering the activity of the 
enzyme is increased after chronic treatment with morphine [98]. 
This dipeptidylaminopeptidase has been named "enkephalinase" and is 
distinct from angiotensin converting enzyme [137]. The term 
"enkephalinase" is rather an unfortunate choice as it implies a degree of 
specificity towards the pentapeptides that is not to displayed by the enzyme, 
which is capable of hydrolysing a variety of neuropeptides [3]. For example 
the enzyme hydrolyses angiotensin I and II [44], neurotensin, bradykinin, 
oxytocin [4], substance P [105], beta-lipotropin 61-69 [67] and gamma-
endorphin [67]. The enzyme also displays a wide tissue distribution being 
found in the kidney brush border [13] and in the microvillar membrane of 
pig intestine [32]. Indeed the enzyme content of these peripheral tissues is 
higher than that found in the brain [45,92]. More fully the enzyme is now 
classified as E.C. 3.4.24.11. Several inhibitors of opioid degrading 
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enzymes appear to show activity in vivo and in vitro. Thus thiorphan, a 
synthetic, highly potent site directed inhibitor ofE.C. 3.4.24.11 produces 
analgesia in the tail flick test when administered to mice, in addition to 
increasing the potency of opioid peptides in bioassays [27,35,107, l31a]. 
A relatively new inhibitor of enkephalin degradation, kelatorphan, is able to 
inhibit all three enzymes responsible for the degradation of the opioid 
pep tides [43]. Kelatorphan is more potent at inhibiting the degradation of 
endogenous and exogenous enkephalin than bestatin or thiorphan or a 
combination of both [35,43,163]. 
ONTOGENY OF OP/OID PEPTIDES 
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The ratios of the various opioid peptides differ not only across brain 
regions, they also vary with age. The levels of all opioid peptides, within 
the c.n.s. increase from birth to adult animals, for example the beta-neo-
endorphin content ofrat neurointermediate pituitary increasing about 1000 
fold over this period [139]. An exception to this rule is beta-endorphin, 
which is not present in the spinal cord of adult animals but can be detected 
in embryonic spinal cord tissue [61]. The levels ofrat striatal [Leu] and 
[Met]enkephalin increase 11 fold from birth to 21 days, however the level 
of striatal [Leu]enkephalin develops more rapidly than that of 
[Met]enkephalin. Moreover the ratio of [Leu] to [Met]enkephalin is not 
constant throughout post-natal development and in addition a variation in the 
ratio occurs between brain regions [122]. In the rat neurointermediate 
pituitary the ratio of dynorphin 1-8 to dynorphin 1-17 at birth is 1:3 whereas 
in the adult the ratio falls to I :0.8. A similar pattern is seen in the ratio of 
beta-neo-endorphin to alpha-neo-endorphin, in newborn rats compared to 
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adult rats [139J. It would appear, therefore, that the enzymes responsible for 
cleaving single basic amino acid residues are not fully developed at birth. 
There is little change in aminopeptidase activity from birth to adulthood in 
either rat cortex or striatum [122J, adult levels are only twice those recorded 
at birth, the maximum level being reached within 1-2 weeks. In contrast the 
level of dipeptidyIcarboxypeptidase ("enkephalinase" E.C. 3.4.24.11) 
displays a 6 fold increase during development, with a time course parallel to 
changes in both [LeuJ and [MetJenkephalin levels and total opioid receptor 
binding capacity [122J. 
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AIMS 
In various brain regions the ratio of prodynorphin and proenlcephalin A 
derived products differ from the ratios found within the pro hormones. Of 
special interest are [Leu]enkephalin and [Met]enlcephalyl-Arg6_Gly7-Leu8 
which have the predicted ratio of 1:1, as both peptides occur in single copies 
within the proenlcephalin A molecule. However the actual ratio varies from 
0.5 to 2.1, being especially high in the substantia nigra [178]. The levels of 
prodynorphin products are also high in the substantia nigra, in particular 
products of low molecular weight, for example dynorphin 1-8. This allows 
for the possibility that the high ratio of [Leu]enkephalin to [Met]enlcephalyl-
Arg6-Gly7-Leu8 is as a result of [Leu]enlcephalin being processed from 
prodynorphin [138]. Indeed, as cited earlier, lesion studies have shown that 
in the striatonigral pathway [Leu]enlcephalin is produced by dynorphinergic 
neurons [176]. 
It is the aim of the present study to investigate the nature and distribution of 
the possible enzymic production of [Leu]enlcephaIin from dynorphin 1-8. 
This metabolism will be studied in various regions of the rat c.n.s. but 
attention will be focused on the spinal cord as this is an important site for 
the modulation of nociceptive information and contains high levels of 
dynorphin 1-8 The effect of this enzymatic metabolism on the receptor 
selectivity of dynorphin 1-8 will be investigated in the isolated myenteric 
plexus longitudinal muscle of the guinea-pig. The physiological 
consequences of such a metabolism will be discussed. 
CHAPTER 2 
Materials and Methods 
MATERIALS AND EQUPlMENT 
Peptides 
Tyrosine; tyrosyl-glycine; tyrosyl-glycyl-glycine; leucyl-leucine. 
Sigma Chemical Company, England 
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Tyrosyl-glycyl-glycyl-phenylalanine; Leucine-enkephalin ( [Leu]enkephalin ); 
[Leu]enkephalyl-Arg6; [Leu]enkephalyl-Arg6-Arg7; dynorphin 1-8; DAGOL 
( [D-Ala2,MePhe4,Gly-oI5]enkephaIin ); DADLE ( [D-Ala2,D-
Leu5]enkephaIin); Beta-Endorphin; metorphamide, dynorphin 1-17; dynorphin 
1-13, Methionine-enkephaIin ([Met]enkephalin) and [Met]enkephalyl-Arg6-
Gly7-Leu8. 
Cambridge Research Biochemicals, England 
Dmgs 
Naloxone 
Sigma Chemical Company, England 
Thiorphan; bestatin 
Cambridge Research BiochemicaIs, England 
The following dmgs were kindly donated: 
Morphine 
McFarlane Smithand Co., Edinburgh, Scotland 
Captopril 
Merck, Sharp and Dohme, England 
Beta-Funaltrexamine (Beta-FNA) and nor-Binaltorphamine (nor-BN!) 
Dr. A. G. Hayes, Glaxo Pharmaceuticals, England 
M8008 (l6-methylcyprenorphine) 
Dr. C. F. C. Smith, Reckitt and Colman Pharmaceutical Division 
N-[-(RS)-carboxy-2-phenylethyl]-Ala-Ala-Phe-p-aminobenzoate 
N-[-(RS)-carboxy-3-phenylpropyl]-Ala-Ala-Phe-n-arninobenzoate 
Dr. M. Orlowski, Mt. Sinai School of Medicine, New York, U.S.A. 
Radiochemicals 
[tyrosyl-3,5-3H(N)]-Dynorphin 1-8 (27.6 Ci/mmol) 
Du Pont, NEN Research Products, England 
Chemicals 
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Trizma base (Tris[hydroxymethyI1arninomethane hydrochloride) and HEPES 
(N-[2-hydroxyethaneJpiperazine-N'-[2-ethanesulphonic acid]) buffer 
Sigrna Chemical Company, England 
Ecoscint, scintillation fluid 
National Diagnostics, England 
Acetonitrile, trifluroacetic acid, triethylamine all HPLC grade 
Fisons Chemical Company, England 
All other chemicals were of analytical grade 
Physiological Solutions 
Formula for Krebs solution 
. NaCI, 118; NaHC03,29; KCI,4.7; CaCI2, 2.5; MgS04, 4.0; KH2P04, 
1.2; Glucose, 11.1 (mM) 
Formula for Krebs-HEPES buffer 
NaCI, 118; NaHC03, 29; KCl,4.7; CaCI2,2.5; MgS04, 4.0; KH2P04, 
1.2; Glucose, 11.1; HEPES, 25 (mM) 
Animals were supplied by the following: 
Male Wistar rats (250-300g), pregnant female rats 
Animal Unit, University of Nottingham, Sulton Bonnington 
Male Dunkin-Hartley guinea-pigs (300-4oog) 
David Hall, Newchurch, Bunon-upon-Trent 
Animals were fed on a standard laboratory diet and kept on a 12hr light/dark 
cycle at a temperature of 20oe. 
Equipment 
The following items of equipment were used throughout the project; 
McIlwain tissue chopper 
Gilson HPLC system including: 
Gilson Holochrome UV variable wavelength detector 
Altex ODS C18 reverse phase column 
SRI square wave stimulators (~N",n:I) 
Washington 400 MD2R chart recorder 
Isotonic transducers (Hanod bioscience) 
Phillips PW4700 liquid scintillation counter 
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METHODS 
1. PURITY OF [3HjDYNORPHIN 1-8 
A sample of [3H] dynorphin 1-8 was analysed for purity using HPLC. A llll 
sample of the radiolabelled dynorphin 1-8 was mixed with IOIlI of a 100llM 
solution of un la belIed dynorphin 1-8. The mixture was then applied to an Altex 
ODS C18 reverse phase column and was eluted using the following gradient 
system: 
Time (min) %B in A 
o 50 
20 90 
Flow Rate (ml/min) 
2 
2 
Solvent A: 26mM trifluroacetic acid, to pH 3 with triethylamine 
Solvent B: 50% acetonitrile in 13mM trifluroacetic acid, to pH 3 by 
triethylamine 
Fractions were collected every 30 seconds. 3ml of Ecoscint scintillation fluid 
were added to each fraction which were then counted for radioactivity. Three 
llll samples of [3H]dynorphin 1-8 were also counted for radioactivity, in order 
to calculate the percentage recovery off the column. Radioactivity that co-eluted 
with the marker peptide, monitored at 2S0nm, was assumed to represent 
[3H]dynorphin l-S. 
The percentage recovery off the column was greater than 98%. Each batch of 
[3H]dynorphin 1-8 used was greater than 97% pure by this method. 
Area Weight (mg) 
Medulla 233±9 
Cortex 812± 35 
Striatum lO3±6 
Hippocampus 120±6 
Hypothalamus 106±7 
Cerebellum 236±6 
Table 2.1 : Weights of various regions from the rat c.n.s. 
Values represent mean ± standard error of mean 
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2. METABOUSM STUDIES 
a.Brain 
Male Wistar rats (250-300g) were killed by decapitation between 9.30 and 
lOam, and the brains immediately removed and placed on ice. The brains were 
dissected according to the method of Glowinski and Iverson (51). Each area 
was weighed [Table 2.1] and then chopped into O.5mm cubes, using a 
Mcllwain tissue chopper. The tissue was placed in 4ml polypropylene test tubes 
and washed a minimum of three times with Krebs solution buffered with 25mM 
HEPES at 37°C. Each area was then suspended in buffer to give a final tissue 
concentration of 200mg/m1. To a 50111 sample (10mg of tissue) of the final 
tissue suspension was added, where appropriate, enzyme inhibitors (diluted 
from distilled water stock solutions in Krebs/HEPES in a volume no greater 
than 30111) and the final volume of the reaction mixture was adjusted to 1ml with 
Krebs/HEPES. Enzyme inhibitors, where added, were preincubated with the 
tissue for various times [Table 2.2], then [3H]Dynorphin 1-8 was added to give 
a final concentration of 12nM. After varying incubation times, at 37°C, the 
reaction was terminated by the addition of phosphoric acid to give a fmal 
concentration of 50mM. The reaction tubes were immediately placed on ice. A 
500111 sample of supernatant from each tube was filtered through cellulose 
nitrate filters (pore size 0.45Jlffi) and frozen at _20°C prior to separation by 
HPLC. Separations were carried out within 48hrs of freezing. 
Time course studies were linearised and tU2valuescalculated. 
b. Lumbar-Sacral Spinal Cord 
Male Wistar rats were killed by decapitation between 9.30 and lOam. The spinal 
cord contained within vertebrae below the second rib was removed and placed 
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on ice. The cord was chopped coronally into slices lmm thick. The slices were 
weighed into lOmg units, each unit being chopped further into 0.5mm cubes. 
The tissue was then treated as described above for brain tissue. 
c. Guinea-pig Cerebellum 
Male Dunkin-Hartley guinea-pigs were killed by cervical dislocation. The 
cerebella were removed and placed on ice then chopped coronally into slices 
Imm thick. The slices were weighed into IOmg units, each unit being chopped 
further into 0.5mm cubes. 
The tissue was then treated as described above for rat brain tissue. 
d. Myenteric Plexus Longitudinal Muscle 
Male Dunkin-Hartley guinea-pigs were killed by cervical dislocation. The ilea 
were removed, after discarding IOcm lengths immediately after the pyloric 
sphincter and immediately prior to the ileal-caecal junction the remaining ilea 
were flushed of their contents and placed in Krebs solution aerated with 5% 
CO2 in 95% 02 at 37°C. The myenteric plexus longitudinal muscle was 
removed from each ileum by placing the ileum over a Im1 glass pipette and 
gently wiping the longitudinal muscle with cotton wool soaked in Krebs buffer. 
The myenteric plexus longitudinal muscle was cut into 3 inch strips 
(approximately lOOmg) and chopped into 0.5mm slices. The slices were then 
treated as for brain tissue described above. 
Inhibitor Pre-Incubation Time (min) 
All endogenous pep tides N.P. 
Dynorphin 1-9 N.P. 
DAGOL 15 
DADLE 15 
Morphine 15 
PMSF 15 
DTI 15 
NEN\ 15 
nCMB 15 
Q-Phen 15 
EDTA 15 
Table 2.2 : Pre-incubation times for various inhibitors used to prevent the 
metabolism of dynorphin 1-8. 
N.P. = not pre-incubated 
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e. Rat Ventricular Muscle 
Male Wistar rats were decapitated between 9.30-10am and the hearts removed 
and placed in Krebs aerated with 5% CO2 in 95% 02 at 37°C. The ventricle 
tissue was dissected from the atria and chopped as for brain tissue. 
3. SEPARATION OF METABOLIC PRODUCTS BY HPLC 
An 80~1 sample of reaction mixture was added to 20~1 of a marker peptide 
solution containing the following, all at a concentration of 100~g/m1: 
tyrosine; tyrosyl-glycine; tyrosyl-glycyl-glycine; tyrosyl-glycyl-glycyl-
phenylalanine; [Leu]enkephalin; [Leu]enkephalyl-Arg6; [Leu]enkephalyl-Arg6-
Arg7 and dynorphin 1-8. The resulting mixture was applied to an AItex ODS 
C18 reverse phase column and was eluted using the following gradient at a flow 
rate of 1m1!min: 
Time (min) 
o 
15 
45 
50 
%B inA 
15 
30 
65 
75 
Solvent A: 26mM trifluroacetic acid, to pH 3 with triethylamine. 
Solvent B: 50% acetonitrile in 13mM trifluroacetic acid, to pH 3 with 
triethylamine. 
This gradient was not adequate for the accurate separation of the tyrosine, 
tyrosyl-glycine and tyrosyl-glycyl-glycine fractions. These three N-terminal 
fragments were therefore collected together and separated further using the 
following gradient at a flow rate of 0.5mI/min: 
Time (min) 
o 
20 
Solvents A and B as above. 
%BinA 
o 
5 
Peaks were monitored at 2SOnm and fractions co-eluting with the marker 
pep tides were collected in 0.5ml aliquots in scintillation minivials. Ecoscint 
scintillation fluid (3mI) was added to each of the fractions which were then 
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counted for radioactivity. Three SOlll samples of incubation mixture were also 
counted for radioactivity, in order to calculate the percentage recovery off the 
, 
column, which was 94.1 ± O.S% [n=25]. Metabolite formation was calculated 
as percentage of total radioactivity recovered from the column. 
4. ISOLATED TISSUE STUDIES 
a. Preparation a/Myenteric Plexus Longitudinal Muscle/or Electrical 
Stimulation 
Male Dunkin-Hart1ey guinea-pigs (300-400g) were killed by cervical 
dislocation. The ileum was immediately removed, flushed of its contents, and 
placed in Krebs solution at 37°C aerated with 5% CO2 in 95% 02. Strips of 
myenteric plexus longitudinal muscle were removed and mounted in 3mI organ 
baths previously coated with silicon to reduce adsorption of peptides onto the 
glass surface. Tissues were bathed constantly in Krebs at 37°C, aerated with 
5% C02 in 95%02. After allowing a recovery period of one hour, each plexus 
was stimulated through platinum ring electrodes using square wave pulses at 
supramaximal voltage at a frequency of 0.16Hz and a pulse width of 400~s. 
Contractions were recorded isotonically. 
b. Experimental Procedure 
i. Agonist Potencies 
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Agonists were added to the tissue baths 30min after electrical stimulation 
commenced. Agonist inhibition of contraction was allowed to reach a plateau 
and then washed out. The concentration of agonist required to reduce the twitch 
height to half its maximum value (ICso) was determined. Where used, the 
peptidase inhibitors captopril, 1OJ.lM; bestatin, lO~M; thiorphan, O.3~M 
(hereafter collectively referred to as the peptidase inhibitor cocktail) were 
incubated with the tissue for 30min prior to the addition of agonist. In some 
cases varying concentrations of N-[(R,S)-carboxy-2-phenyIethyl]Ala-Ala-Phe-
pAB or N-[(R,S)-carboxy-3-phenylpropyly]Ala-Ala-Phe-pAB were added in a 
similar manner. Following each application of agonist, tissues were washed by 
overflow until maximum contraction was restored to control levels. 
ii. Measurement of Antagonist Affinities 
Antagonists were preincubated with the guinea-pig myenteric plexus 
longitudinal muscle for the following times: naloxone, 20min; M8008, 3Omin; 
nor-binaltorphamine, 45min, prior to the addition of agonist. Dose-response 
curves for agonists were obtained before the addition of antagonist and then 
repeated in the presence of varying concentrations of antagonist. Dose-ratios 
were calculated at 1Cso values and Schild [5] plots constructed (as described in 
section 2.5). Antagonists were removed from the tissue by continuous w~shing 
until the response to added agonist was fully recovered. All dose-response 
curves were cumulative, with 10min between subsequent dose response curves to agonists. 
Tissues were maintained; under 19 resting tension. 
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iii. Irreversible Inhibition by Beta-Funaltrexamine 
Dose-response curves for agonists in the guinea-pig myenteric plexus 
longitudinal muscle were constructed. After washout of the agonist lOOnM beta 
funaltrexamine (beta-FNA) was added to the bath and the tissue was then 
incubated with the beta-FNA for 30min. After this time the beta-FNA was 
removed by continuous washing for 60min or until maximum control 
contraction was attained. Agonist dose-response curves were then repeated. 
Dose-ratios before and after beta-FNA were calculated at 1C50 values. 
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5. THE SCHILD PLOT 
In order to define the receptor at which an agonist acts it is necessary to employ 
an antagonist. From the ability of the antagonist to compete with an agonist at 
any given receptor type a value ~ as the Ke or pA2 can be determined. 
This value varies between receptor type and is a measure of the affinity of an 
antagonist for a particular receptor. In addition the Ke value is also a measure of 
the ability of any given agonist to displace a particular antagonist from a 
particular receptor site and consequently can function as an indicator of the 
receptor selectivity of a given agonist. Of particular importance is the slope of 
the Schild plot which should be unity if a selective antagonist has been 
displaced from a single receptor type (but see page 39). 
A competitive antagonist can be regarded as a drug that interacts reversibly with 
a set of receptors to form a complex, but unlike an agonist-receptor complex, it 
fails to elicit a response (ie the antagonist has no intrinsic activity). The 
antagonist-receptor complex can therefore be characterised by a dissociation 
constant. The interaction can be expressed as: 
kl 
Antagonist + Receptor .... i===t.Antagonist-Receptor 
Complex 
[A) [R) [AR) 
where k) and kz are the association and dissociation rates for the complex. 
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According to the law of mass action the rates of the forward and reverse 
reactions are the same once equilibrium is attained therefore: 
therefore: 
k2 = Ke= [A][R] 
[AR] (equation 1) 
where Ke is the antagonist dissociation constant. 
When both an antagonist and an agonist are present, the various interactions 
with receptors can be expressed thus: 
[D] + [A] + [R] ~ • [AR] + [DR] 
where [D] is the concentration of agonist and [DR] is the concentration of the 
agonist-receptor complex. 
Now if the total number of receptors is [RT] then the number of free receptors 
[R] can be expressed as: 
[R] = [RT]-[AR]-[DR] 
Dividing through by [DR] 
[R] [RT] [AR] 
=--- -1 
[DR] [DR] [DR] (equation 2) 
The principles applied to the antagonist are valid for an agonist therefore: 
KD = [D][R] [R] = KD 
--- ie 
(equation 3) 
[DR] [DR] [D] 
where KD is the dissociation constant for the agonist. 
Substituting equations 3 and then 1 into equation 2: 
--- -1 
[D] [DR] [DR] 
and therefore 
which reduces to 
Ko = [RT] [A][R] [D)[R] 
- --+ -1 
[D) [DR] Ke Ko 
KD = [RT] [A]Ko 
[D] [DR] Ke [D) 
-1 
multiplying throughout by Ke[D] : 
rearranging 
therefore 
Ko Ke = [RT]KdD] - [A]Ko -Ke[D] 
[DR] 
KoKe + [A]Ko + Ke[D] = [RT]Ke[D] 
[DR] 
[RT] = KoKe +Ko[A] + Ke[D] 
[DR] Ke[D] 
(equation 4) 
The reciprocal of this equation gives the fraction of receptors occupied by an 
agonist in terms of concentrations and dissociation constants of agonist and 
37 
antagonist. Assuming that [DR]![RT] (ie. the proportion of receptors occupied 
by the agonist) is equal to ElEmax , the ratio of effect produced by a given dose 
of agonist to the maximal possible effect, then the reciprocal of the equation 
expresses any given response to an agonist as a fraction of the maximum 
possible response. Indeed when the concentration of agonist is zero then 
equation 4 simplifies to: 
[DR] = [D) (equation 5) 
[RT] [D]+Ko 
Equation 4 also predicts that the linear portion of the agonist concentration 
response curves carried out in the presence and absence of a competitive 
antagonist will be parallel, but displaced to the right in the presence of 
antagonist. The most important feature of competitive antagonism is that it may 
be overcome by increasing concentrations of agonist ie. the maximum response 
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is not affected by a competitive antagonist. The degree of shift to the right of the 
agonist logarithmic concentration response curve is proportional to the 
antagonist concentration and to the affinity of the antagonist for the receptor. 
The affinity of the antagonist for any given receptor type is inversely 
proportional to the antagonist-receptor dissociation constant Ke. The value of 
the Ke can be determined from the concentration of agonist producing equal 
responses in the absence [Dol and presence [D Al of antagonist. Since the 
response to the agonist is equal, the proportion of receptors occupied is 
assumed to be the same. 
Therefore from equations 4 and 5: 
taking reciprocals 
dividing by denominators 
reducing and rearranging 
reducing 
[Dol Ke[DAl 
= 
[Dol+KD KDKe+KD[Al+Ke[DAl 
[Dol+KD KDKe+KD[Al+Ke 
= 
[Dol Ke[DAl 
, 
I+KD= KDKe KD[Al 
+ 
[Do] Ke[DAl Ke[DAl 
I+KD = KD KD[A] 
-+ 
[Do] [DAl Ke[DAl 
KD = KD[I+[All 
[Dol [DAl[I+Kel 
[DAl [Al 
-1 =-
[Dol [Kel 
+1 
+1 
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The value of the-Ke is independent of the agonist used provided the antagonist 
competes with it for the receptor. 
When the concentration of antagonist ([A2D is such that: 
then 
ie. the value of the dissociation constant for the antagonist is the concentration 
of antagonist with which the ratio of concentrations of agonist producing equal 
responses in its presence [DA) and·absence [Dol equals 2. 
The negative logarithm of the molar concentration of antagonist with which the 
ratio of equi·effective concentrations of agonist in the presence and absence of 
antagonist is two, has been designated by Schild as the pA2 value thus: 
pA2 = -log[A2l = log[I/[A2ll (equation 7) 
Equation 6 can be converted to a form containing pAx where pAx is the 
negative logarithm of the molar concentration of antagonist in the presence of 
which the potency of the agonist is decreased x times. 
taking logs 
x-I = [Axl 
Ke 
log[x-ll = 10g[Axl-logKe (equation 8) 
Equation 8 predicts that the plot of log[x-ll verses 10g[Axl is a straight line, the 
intercept on the 10g[Al axis giving the value ofIogKe or -pA2. The slope of the 
line is I provided the agonist is acting at a single receptor class. Deviation from 
unit slope is consistent with a system of more than one receptor class. However 
departures from linearity for the double log relationship for a system of one 
receptor type have been predicted and observed in a variety of experimental 
situations. 
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There are several reasons why this error can occur: 
I).Tissue uptake of agonist, 
2). The use of insufficient incubation times for the antagonist resulting in a non-
equilibrium situation, 
The first two problems result in slopes of less than unity. 
3).The use of antagonists that are toxic can result in a slope greater than unity. 
[90]. 
Results throughout are expressed as mean ± standard error of the mean (sem). 
Statistical analysis was carried out using ANOVA analysis of variance followed 
by Dunnett's t-test . Other results were analysed by the Mann Whitney U test 
where stated. 
CHAPTER 3 
Distribution of the Metabolism of 
[3H1Dynorphin 1-8 
41 
INTRODUCTION 
All peptides when in contact with tissue or body fluids are susceptible to attack 
by metabolising enzymes. The opioid peptides are not an exception to this rule, 
for example the hydrolysis of the N-terminal portion of the pentapeptides was 
described immediately following their isolation and sequencing [57 ]. 
Several years later the sequencing of the pro hormone for the larger dynorphin 
molecules revealed the dynorphin 1-17 sequence to be the precursor for 
dynorphin 1-8 which was in turn an extended form of [Leu]enkephalin. The 
ratio of these three pep tides in the c.n.s. does not parallel that found within the 
prodynorphin molecule [138]. Also the ratio of [Leu]enkephalin to 
[Met]~ephalyl-Arg6-Gly7-Leu8, both found in single copies within the 
prohormone proenkephalin A, varied widely throughout the rat c.n.s.[138]. 
This led to speculation that [Leu]enkephalin could be produced from two 
prohormones, namely proenkephalin A and prodynorphin [176]. It was also 
evident that the enzymatic activity responsible for the production of 
[Leu ]enkephalin was not uniform as the ratios of the peptides derived from 
prodynorphin differed across various brain regions [138]. 
The [Leu]enkephalin produced could be formed from the prohormone directly 
or from larger dynorphin molecules by post-translational processing. Here we 
examine the extent to which dynorphin 1-8 is metabolised by the rat spinal cord 
and investigate the distribution of this metabolism within the rat and guinea-pig 
c.n.s. and the rat periphery. 
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RESULTS 
Metabolism of [lH]Dynorphin 1-8 by Central Nervous System Tissue 
1.) Rat Spinal Cord 
Incubation of [3H]dynorphin 1-8 (12nM) with slices of rat lumbo-sacral spinal 
cord resulted in the rapid metabolism of the peptide [Fig. 3.1a]. Separation of 
the metaboIites by HPLC [Fig. 3.2] revealed that, following a 20min 
incubation period 80.4 ± 4.1 % of the recovered radioactivity co-eluted with the 
N-tenninal fraction of the peptide (consisting of Tyr, Try-GIy and Tyr-Gly-
Gly). Upon further separation this N-tenninal fraction was seen to be almost 
exclusively composed of PHltyrosine [Fig. 3.3]. The fraction co-eluting with 
the [Leu]enkephalin marker contributed 11.0 ± 3.3% to the radioactivity total. 
Also after 20min only 2.4 ± 1.3% of the radioactivity co-eluted with the parent 
peptide [Fig 3.1a]. Indeed when in contact with the tissue [3H]dynorphin 1-8 
had a half life of just 2.5 ± 0.4 min. 
A 30 min incubation of lumbo-sacral spinal cord slices with the enzyme 
inhibitors captopril (lOIlM); bestatin (lOJlM); thiorphan (O.3IlM) and. 
prior to the addition of PHldynorphin 1-8 resulted in a 
stabilization of the [3Hldynorphin 1-8. Under these conditions the half life of 
the [3Hldynorphin 1-8 increased to 7.3 ± 3.1 min. Although at the end of the 
20min incubation period [3H]dynorphin 1-8 still only constituted 16.2 ± 4.2% 
of the recoverable radioactivity [Fig. 3.1 b 1. The major metabolite formed from 
[3Hldynorphin 1-8 by the spinal cord slices following preincubation with the 
enzyme inhibitors was [3Hl[leulenkephalin, accounting for 60.5 ± 2.2% ofthe 
recoyered radioactivity. The level of recovered N-tenninal fraction 
concomittantly decreased to 9.6 ± 2.2%. 
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In the absence or presence of the enzyme inhibitors the other possible 
metabolites of [3H]dynorphin 1-8 namely, [3H]tyrosyl-glycyl-glycyl-
phenylalanine, [3H][Leu]enkephalyl-Arg6 and [3H][Leu]enkephalyl-Arg6_Arg7 
accounted for 5.1 ± 0.3%, 1.4 ± 0.1 % and 0.7 ± 0.2% respectively of the 
recovered radioactivity following a 20 min incubation period. 
2.) Rat Brain and Guinea·Pig Cerebellum 
In all rat brain areas tested [3H]dynorphin 1-8 (12nM) was readily metabolised 
giving a variety of products. In the presence of the enzyme inhibitor cocktail 
(namely, bestatin, lOIlM; captopril, 10IlM and thiorphan, 0.3IlM) 
[3H][Leu]enkephalin formed the major metabolite following a lOmin incubation 
with c.n.s. tissue [Fig. 3.4]. In all brain regions the amount of recoverable 
rH] [Leu]enkephalin, formed after a IOmin incubation, was greater than that of 
recoverable pH]dynorphin 1-8. Indeed as the level of PH][Leu]enkephalin 
increased a parallel decrease in [3H]dynorphin 1-8 was observed. Thus the 
highest level of intact rH]dynorphin 1-8 was recovered following incubation 
with the hypothalamus, the area least effective at producing 
rH][Leu]~ephalin. In contrast, the cortex produced the greatest amount of 
[3H][Leu]enkephalin, affording 67.0 ± 3.6% of the recoverable activity, with 
rH]dynorphin 1-8 accounting for only 17.8 ± 5.0%. 
The pattern of metabolism recorded using guinea-pig cerebellum was similar to 
that observed using rat C.n.S. tissues [Fig. 3.5]. In the absence of enzyme 
inhibitors, the N-terminal fraction accounted for the largest portion of the 
recovered radioactivity, 49.5 ± 3.2% after a lOmin incubation period, 
rH]dynorphin 1-8 contributing a mere 6.3 ± 2.1 % to the total amount of 
recovered radioactivity. Once again following pre-incubation with the enzyme 
inhibitor cocktail [3H][Leu]enkephalin emerged as the most copious metabolite, 
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affording 55.9 ± 2.4% of the total recovered radioactivity following a 10 min 
incubation period [Fig. 3.5]. 
Peripheral tissues 
1.) Guinea-Pig Myenteric Plexus Longitudinal Muscle (MPLM) 
The production of [3H][Leu]enkephalin from [3H]dynorphin 1-8 was not 
confined to central nervous system tissue. Thus [3H]dynorphin 1-8 was also 
degraded by slices of MPLM with a half life of 2.3 ± 0.5min. Following a 
contact time of 20min only 1.3 ± 0.4% of the added [3H]dynorphin 1-8 was 
recovered. On the other hand the N-terminaI fraction accounted for 
96.3 ± 1.5% of the recovered radioactivity [Fig 3.6a]. On pre-incubation with 
the enzyme inhibitor cocktail the half life of [3H]dynorphin 1-8 increased to 
7.0 ± 1.1min. Following a 20min incubation period the level of recoverable 
[3H]dynorphin 1-8 rose to 14.0 ± 3.8%, whereas the level of N-terminal 
metablites decreased to 31.4 ± 4.9%. Once again [3H][Leu]enkephalin 
emerged as the major metabolite. contributing 41.7 ± 1.0% to the total amount 
ofrecovered activity [Fig. 3.6b]. 
2.) Rat Heart Tissue 
Rat ventrical tissue displayed a similar pattern of metabolism of [3H]dynorphin 
1-8 as that found using c.n.s. tissue [Fig. 3.7]. In the absence of enzyme 
inhibitors the major site of hydrolysis was the N-terminus of the [3H]dynorphin 
1-8 molecule affording an N-terminal fraction accounting for 64.4 ± 7.4% of 
the recovered radioactivity following a lOmin incubation period. 
[3Hl[Leu]enkephalin and intact [3Hldynorphin 1-8 contributing only 
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15.6 ± 2.9% and 16.8 ± 4.8% respectively to the total amount of recovered 
radioactivity [Fig. 3.7]. Preincubation of the ventrical tissue with the enzyme 
inhibitor cocktail increased the amount of recoverable [3H][Leu]enkephalin to 
55.2 ± 2.5% and [3H]dynorphin 1-8 to 19.6± 2.4% .• The N-terminal 
fraction decreased to represent 13.9 ± 0.9% of recovered activity. 
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Figure 3, la: Time course of the metabolism of [3H]dynorphin 1-8 by slices of rat 
lumbo-sacral spinal cord. [3H]dynorphin 1-8 (circles); [3H][Leu]enkephalin 
(squares); [3H]N-terminal fraction (triangles) [n=6] 
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Figure 3,lb: Metabolism of rH]dynorphin 1-8 by slices of rat lumbo-sacral spinal 
cord following a 30 min preincubation with the enzyme inhibitory cocktail (bestatin 
101lM, captopril JOllM, thiorphan O.3lJ.M), [3H]dynorphin 1-8 (circles), 
[3H][Leu]enkephalin (squares), rH]N-terminal (triangles) [n=5] 
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Figure 3.6a : Time course of the metabolism of [3H]dynorphin 1-8 by slices of 
guinea-pig myenteric plexus longitudinal muscle. rH]dynorphin 1-8 (circles); 
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Figure 3.6b : Metabolism of [3H]dynorphin 1-8 by slices of guinea-pig MPLM 
following a 30 min preincubation with the enzyme inhibitory cocktail (bestatin 
101lM, captoprillOllM, thiorphan 0.3IlM). [3H]dynorphin 1-8 (circles), 
[3H] [Leu]enkephalin (squares), rH]N-terminal (triangles) [n=3] 
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Figure 3.7 : Metabolism of [3H]dynorphin 1-8 following a 10 min incubation with slices ofrat ventricle in the absence of and presence of the enzyme 
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DISCUSSION 
The results presented demonstrate that the peptide dynorphin 1-8 is rapidly 
broken down by rat spinal cord tissue in vitro via hydrolysis of the amide bond 
between the N-terminal tyrosine and glycine2. Previous studies have shown that 
the hydrolysis of the N-terminus is not limited to the dynorphin 1-8 molecule, 
indeed a host of opioid peptides appear to be susceptible to attack at this 
position by aminopeptid ,ases [48,91,173]' This is an important cleavage site as 
removal of the N-terminal tyrosine results in a molecule that is unable to bind to 
any opioid receptor [95]. 
Previous studies have reported the presence of a dipeptidylaminopeptidase 
within brain tissue that is capable of releasing TyrLGly2 from opioid peptides 
[25,53]. However no evidence of such activity was detected under the 
incubation conditions presented here. This does not, however, discount the 
possiblity of a rapid turnover of the TyrLGly2 fragment to a single tyrosine 
residue. Similarly no evidence of the hydrolysis of the Gly3-Phe4 bond was 
detected in either the presence or absence of the cocktail of enzyme inhibitors. 
Previous studies have revealed the activity of a dipeptidylaminopeptidase (E.C 
3.4.24.11) that is able to hydrolyse the Gly4-Phe5 bond within [Leu] and 
[Met]enkephalin and similar bonds in a variety of other peptides including 
substance P, cholesystokinin 8 and somatosatin [11,33,98]. However the rapid 
metabolism, to [3H]tyrosine, of the s~equently released [3H]TyrLGly2-Gly3 
fragment again cannot be ruled out. 
Removal of the N-terminal portion of dynorphin 1-8 or more extended forms 
such as dynorphin 1-13 and dynorphin 1-17 results in a molecule that is 
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incapable of eliciting analgesia [147]. However when administered intrathecally 
or intracerebroventricularly (i.e. v.) dynorphins display a wide variety of effects 
in addition to analgesia. Intrathecal application of dynorphin 1-13 or dynorphin 
1-17 causes flaccid paralysis ofhindIimbs and tail [63,129], reduced spinal cord 
blood flow [93], and marked neuropathalogical changes characterised by 
neuronal loss and necrosis through the central grey matter of the lumbo-sacral 
spinal cord [94]. Injections of dynorphin 1-17 given i.c.v. produced 
electroencephalographic changes in the rat [164]. However non of these 
deletrious actions are the result of an interaction with opioid receptors as high 
doses of the opioid antagonist naloxone fail to prevent such actions [94, 147]. 
These non-opioid effects are shared by dynorphin 2-17, dynorphin 2-13 and 
dynorphin 3-13 [129] indicating that perhaps removal of the N-terminal portion 
of the molecule is required before the dynorphin is able to elicit such delitrious 
effects. Smaller dynorphin fragments namely [Leu]enkephalyl-Arg6_Arg7 and 
dynorphin 1-8 do display paralytic effects when administered intrathecally in the 
presence of peptidase inhibition. However, such paralytic effects appear only 
when peptidase inhibitors are co-administered, suggesting a rapid metabolism 
of the molecule is responsible for the lack of effect in the absence of peptidase 
inhibition. These paralytic effects were not observed following injection of 
either [Leu]enkephalyl-Arg6 or [Leu]enkephalin in either the presence or 
absence of peptidase inhibitors [94], though these compounds, in the presence 
of peptidase inhibitors, d~lay naloxone reversible antinociceptive properties in 
the tail flick test. This display of naloxone reversible antinociception by 
[Leu]enkephalyl-Arg6 and [Leu]enkephalin indicates that their enzymatic 
degradation was inhibited and their opioid bioactivities were preserved. 
Likewise i.c.v. administration of the peptidase inhibitors bestatin, thiorphan and 
kelatorphan given alone, or in combination at doses shown to inhibit the 
degradation of the N -terminal portion of the dynorphin molecule, caused a 
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naloxone reversible increase in the latency time in hot plate and tail flick tests 
carried out in mice [27,35,43, 163]. In addition direct intrathecal application of 
kelatorphan, bestatin or thiorphan into halothane anaesthetised rats has the 
ability to reduce the responsiveness of dorsal horn sensory neurons to noxious 
stimuli applied to cutaneous receptive fields [43]. The effectiveness of 
intrathecal application of peptidase inhibitors at eliciting naloxone reversible 
analgesia suggests they are able to potentiate the effects of endogenously 
released dynorphins or enkephalin by preventing their enzymatic degradation. 
The prevention of enzymatic damage to the dynorphin molecule has important 
physiological implications. Studies involving spinal cord trauma have revealed 
the level of dynorphin 1-17 to be elevated at the site of injury in rats [38]. As 
described previously removal of the N -terminus fr;om the dynorphin molecule 
has paralytic effects perhaps therefore contributing f~her spinal injury. 
However the opioid antagonist naloxone improves the recovery from spinal 
cord injury in the cat suggesting that elevated dynorphin levels may also act 
through opioid receptor occupation to slow down or prevent recovery from 
such trauma [37]. 
Inclusion of enzyme inhibi tors in the incubation medium to protect against both 
N- and C-terminal attack results in a partial stabilization of the dynorphin 1-8 
molecule. This is illustrated by an increase in the half-life of the octapeptide 
with a concomittant decrease in the level of recoverable [3H]tyrosine following 
a 20min incubation period. Importantly, under these inhibitory conditions the 
pentapeptide [3H][leu]enkephalin is the major metabolite contributing more to 
the total recovered radioactivity than intact [3H]dynorphin 1-8. 
Gillan and co-workers [48] described the production of [Leu]enkephalyl-Arg6 
and [Leu]enkephalyl-Arg6_Arg7 from dynorphin 1-8, the two peptides 
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affording 5-10% of the total recovered radioactivity following a 120min 
incubation with suspensions of guinea-pig brain membranes at Doe. However in 
the present studies the sum of both peptides contributed less than 3% to the total 
recovered activity. Again the rapid turnover of these peptides could explain the 
discrepency between the two sets of data, this however seems unlikely as one 
would expect to observe an increase in the level of such metabolites upon the 
addition of enzyme inhibitors to the incubation medium. 
Tissue from each brain region studied was seen to liberate [Leu] enkephalin 
from dynorphin 1-8. Indeed, when peptidase inhibitors were included in the 
incubation medium this pentapeptide became the major metabolite. Metabolism 
of this type, therefore appears not to be confined to areas containing a specific 
receptor population. However, the ability of all areas of c.n.s. tissue assayed to 
produce a delta/mu-preferring ligand in [Leu]enkephalin from the kappa-
preferring dynorphin 1-8 confers a high degree of flexibility of response on the 
dynorphinergic system within the c.n.s. and possibly in the periphery. As 
described in the introduction, a dynorphinergic system of [Leu]enkephalin 
production has been located in vivo in the neuronal pathway between the 
stiatum and the substantia nigra in the rat [176]. 
The apparent lack of a relationship between metabolism and opioid receptor 
specificity might seem to be confirmed by studies in guinea-pig cerebellum. The 
guinea-pig cerebellum contains an opioid receptor popUlation of which 80% is 
of the kappa type [15]. The production of the delta-preferring [Leu]enkephalin 
from dynorphin 1-8 by this tissue is perhaps therefore somewhat surprising if a 
specific role for this metabolism is envisaged. However recent evidence 
suggests that the guinea-pig cerebellum contains a low population of mu 
receptors in addition to the kappa receptor population [131]. The ability of this 
tissue to produce [Leu]enkephalin, which can interact at the mu receptor [95,96] 
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may therefore again serve to confer a level of flexibility on dynorphinergic 
systems within the guinea-pig cerebellum. It may be that if a greater degree of 
refinement can be attained then a relationship between opioid receptor type and 
location of the enzyme(s) may be observed. 
The metabolism of dynorphin 1-8 is not confined to c.n.s. tissue, both the 
guinea-pig myenteric plexus longitudinal muscle and rat ventrical muscle were 
able to produce the pentapeptide from dynorphin 1-8. Previous studies have 
described the production of [Leu]enkephalin from dynorphin 1-9 by slices of 
mouse vas deferens in the presence of enzyme inhibitors [108]. In the present 
study both the myenteric plexus longitudinal muscle of the guinea-pig and rat 
ventrical muscle are able to degrade dynorphin 1-8 via the cleavage of the N-
terminal tyrosine. Again incorporation of the cocktail of enzyme inhibitors into 
the incubation medium results in the protection of the octapeptide, illustrated in 
the MPLM by an increase in the half-life of dynorphin 1-8. This protection of 
the octapeptide is not at the expense of [Leu]enkephalin since, in both tissues, 
[Leu ]enkephalin forms the major metabolite in the presence of peptidase 
inhibitors. 
It would appear, therefore, in all tissue systems investigated that 
[Leu]enkephalin is formed via a direct cleavage of the Leu5-Arg6 bond within 
the dynorphin 1-8 molecule. The reasons supporting this are twofold: 
1.) There is no evidence of a sequential breakdown of dynorphin 1-8 since the 
metabolic products [Leu]enkephalyl-Arg6 and [Leu]enkephalyl-Arg6_Arg7 
represent less than 2% of the total recovered radioactivity under both inhibited 
and uninhibited conditions, although a rapid turnover of such metabolites 
cannot be completely ruled out 
2). The production of [Leu]enkephalin is markedly enhanced when the reaction 
is performed in the presence of enzyme inhibitors designed to prevent 
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degradation of the N- and C-termini of the octapeptide [107]. These inhibitors in 
addition to protecting dynorphin 1-8, also appear to stabilize any 
[Leu]enkephalin formed, thereby substantially increasing the level of 
recoverable pentapeptide. 
In light of these results the production of [Leu]enkephalin from dynorphin 1-8 
may be viewed as a conversion process rather than a metabolic inactivation. 
CHAPTER 4 
Characterisation of the Metabolism of 
. [3H1Dynorphin 1-8 
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INTRODUCTION 
The metabolism of dynorphin 1-8 to [Leu )enkephalin, discussed in Chapter 3, 
is widespread and apparently the result of a direct hydrolysis of the Leu5-Arg6 
bond within the octapeptide. A survey of the literature suggests there are two 
known possible candidate enzymes responsible for this metabolism. The fIrst is 
a metalloendopeptidase initially isolated from rat brain and classifled as EC 
3.4.24.15 [119). The second is a thiol protease designated endo-oligopeptidase 
A [18). Both enzymes are able to hydrolyse opioid peptides but are not specifIc, 
being able to effIciently hydrolyse a variety of other neuropeptides. As both 
peptides appear able to liberate [Leu)enkephalin from dynorphin 1-8 it is 
possible that one or other or a combination of these two enzymes may be 
responsible for the dynorphinergic production of [Leu)enkephalin. 
In the following chapter the nature of the enzyme responsible for the hydrolysis 
of dynorphin 1-8 to [Leu)enkphalin is examined. Results with a variety of 
substrates give information on the active site of the enzymic reaction and a 
series of inhibitors will enable some characterisation of the enzymic reaction. In 
addition, the ability oftwo active site directed inhibitors ofE.C. 3.4.24.15. to 
prevent the metabolism of dynorphin 1-8 to [Leu)enkephalin will be studied. 
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RESULTS 
1.) Pep tides as competing substrates 
In order to uncover the optimum substrate length for the enzyme involved in the 
formation of [Leu]enkephalin the degradation pattern of dynorphin 1-8, in the 
presence of the enzyme inhibitor cocktail (bestatin 10).lM, thiorphan O.3).lM and 
captoprill0llM) was studied and compared to the pattern of metabolism 
obtained when, in addition to the above inhibitory cocktail, other opioid 
peptides were added to the incubation medium as competing substrates. As can 
be seen from Fig 4.1 the production of [3H][Leu]enkephalin from 
[3H]dynorphin 1-8 (12nM), by slices of rat lumbar-sacral spinal cord, is 
inhibited to a varying degree by a variety of opioid peptides added at a 
concentration of IIlM. The pentapeptides [Leu] and [Met]enkephalin do not 
significantly inhibit the production of [3H][Leu]enkephalin nor do they increase 
the percentage ofrecoverable [3H]dynorphin 1-8. Inhibition of 
[3H][Leu]enkephalin production however, increases with the length of the 
opioid peptide added as competitor [Fig. 4.1]. The most potent peptide in this 
respect is dynorphin 1-13, which inhibits the production of 
[3H][Leu]enkephalin by 88.8 ± 3.5%. In addition the presence of the peptide 
dynorphin 1-13 results in a large increase (158.6± 14.2%) in the level of 
recoverable [3H]dynorphin 1-8 compared with the amount ofrecovered 
[3H]dynorphin 1-8 in the absence of dynorphin 1-13. In contrast dynorphin 1-
17 and the large opioid peptide beta-endorphin have negligible effect on the 
metabolism of [3H]dynorphin 1-8. Stable analogues of the smaller opioid 
peptides namely DAGOL (101lM) and DADLE (lO).lM) also failed to effect the 
metabolism of [3H]dynorphin 1-8 as did the alkaloid morphine (lO).lM) and the 
kappa agonist U50 488H (10).lM). 
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2.) Other Non-Specific Inhibitors 
A variety of other enzyme inhibitors, preincubated with the spinal cord tissue 
for 30min at 37°C, were also assayed for their ability to inhibit the production of 
[3H] [Leu]enkephalin from [3H]dynorphin 1-8. These experiments were 
performed in IRIS buffer to avoid possible interference from metal ions present 
in Krebs buffer in addition to the usual Krebs/HEPES buffer system. The TRIS 
buffer did not alter the metabolism of [3H]dynorphin by rat spinal cord. 
The metal chelator EDTA (lmM) failed to inhibit the production of 
[3H][Leu]enkephalin, as did the serine protease inhibitor 
phenylmethylsulphonylfluoride (pMSF) (lmM). The chelating agent Q-
phenanthroline (lmM) caused a 28.2 ± 8.6% inhibition of 
[3H] [Leu]enkephalin production [Fig. 4.2]. However this inhibitory effect may 
not be due to metal chelation because repeating the experiment in Krebs/Hepes 
buffer also resulted in an inhibition of [3H] [Leu]enkephalin production 
[Fig. 4.2]. The thiol blocking agents N-ethylmalemide (NEM) (lmM) and p-
hydroxymercuribenzoate (J2HMB) (O.2mM) caused a reduction in 
[3H] [Leu]enkephalin that was equieffective in both TRIS and Krebs/Hepes 
buffer systems, ll. CMB being the most effective, O.2mM resulting in a 93% 
inhibition of metabolism [Fig. 4.2]. 
3.) Site Directed Inhibitors 
Preincubation of spinal cord tissue, at 37°C for 30min, with the site directed 
inhibitor of EC 3.4.24.15, namely N-[(RS)-carboxy-2-phenylethyl]Ala-Ala-
Phe-pAB (N-[(RS)-carboxy-2-phenylethyl]Ala-Ala-Phe-pAB) resulted in a 
concentration dependent inhibition of dynorphin breakdown [Fig. 4.3a]. A 
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concentration of 100)lM inhibited [3H][Leu]enkephalin production by 96.7%. 
Preincubation with a more recently synthesized inhibitor ofEC 3.4.24.15, 
namely N-[(RS)-carboxy-3-phenylpropyl]Ala-Ala-Phe-pAB (N-[(RS)-carboxy-
3-phenylpropyl]Ala-Ala-Phe-pAB) resulted in a far more potent inhibition of 
metabolism. Thus at a concentration of 0.3)lM a 90.2 ± 2.8% inhibition of 
[3H][Leu]enkephalin was seen, the amount of recovered rH]dynorphin 1-8 
increasing from 34.3 ± 7.3% to 90.1 ± 3.1 % [Fig. 4.3b]. 
Production of [3HJlleu]enkephalin from [3H]dynorphin 1-8 by peripheral tissue 
was also inhibited by the site directed inhibitor N-[(RS)-carboxy-3-
phenylpropyl]Ala-Ala-Phe-pAB. Preincubation of guinea-pig MPLM with the 
inhibitor at a concentration of O.3)lM caused a 93.5 ± 1.9% inhibition of 
[3H] [Leu]enkephalin production after a 20min incubation period [Fig. 4.4]. 
Likewise the production of rH] [Leu]enkephalin by rat ventrical muscle was 
almost completely inhibited by O.3uM N-[(RS)-carboxy-3-phenylpropyl]Ala-
Ala-Phe-pAB [Fig. 4.5]. The percentage of recoverable rH]dynorphin 1-8 
increasing from 19.6 ± 2.4% to 86.7 ± 1.8% on the addition of O.3)lM N-
[(RS)-carboxy-3-phenylpropyl]Ala-Ala-Phe-pAB to the incubation medium. 
A large overall protection of rH]dynorphin 1-8 can thus be obtained when the 
protease enzymes within the metabolising tissue are inhibited with the site 
directed inhibitor N-[(RS)-carboxy-3-phenylpropyl]Ala-Ala-Phe-pAB in 
addition to the standard enzyme inhibitor cocktail of bestatin, captopriI and 
thiorphan [Fig. 4.6] .. 

Figure 4.1 : Key to abbreviations 
[Leu]enk......................................... [leu]enkephalin 
[Met]enk............................. ............ [met]enkephalin 
1-6................................................ [leu]enkephalyl-Arg6 
1-7................................................ [leuJenkephalyl-Arg6_Arg7 
1-8 ................................................ dynorphin 1-8 
1-9 ....................................... : ........ dynorphin 1-9 (dynorphin 1-8-1s09) 
1-13 ............................................... dynorphin 1-13 
1-17 ............................................... dynorphin 1-17 
[MetlenkAGL. ................................... [metlenkephalyl-Arg6-Gly7-Leu7 
B-end ............................................. beta-endorphin. 
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Figure 4.1 : The ability of various opioid pep tides to inhibit the production of [3H][Leu]enkephalin from [3H]dynorphin 1-8 following a 10 min incubation 
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Figure 4.2: The ability of various chemical enzyme inhibitors to prevent the production of [3H] [Leu]enkephalin from [3H]dynorphin 1-8 following a 10 
min incubation with slices of rat spinal cord. Experiments were carried out in TRIS buffer (stippled column) and in Krebs buffer (hatched column) 
[n=4] Values represent mean ± standard error of mean 
100 
c 
~ g 75 
_"0 
of:! 
CD. 
.2 C 
-.-:c ca 50 
'-s: s:c. 
.5Q) 
~O .:.: o~ c 
Q) 
:; 25 
.3 
~ 
O+-----~----~----_.----_r----_, 
~ .~ -6 ~ ~ -3 
Log [N-[-(R,S~rboxy-2-phenylethyll-Ala-Ala-Phe-pABl (M) 
Figure 4.3a : Dose-response study of the ability of the EC 3.4.24.15 inhibitor N-
[(R,S)-carboxy-2-phenylethyl)-Ala-Ala-Phe-pAB to inhibit the production of 
[3H][Leu]enkephalin from [3H]dynorphin 1-8 following a 10 min incubation with 
rat spinal cord in the presence of bestatin lOJ.LM, captoprillOJ.LM and thiorphan 
0.3J.LM. [n=3 except where error bars are absent when n=2] 
Values represent mean ± standard error of mean 
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Figure 4.3b : Dose-response study of the ability of the EC 3.4.24.15 inhibitor N-
[(R,S)-carboxy-3-phenylpropyl]-Ala-Ala-Phe-pAB to inhibit the production of 
PH] [Leu]enkephalin from [3H]dynorphin 1-8 following a 10 min incubation with 
rat spinal cord in the presence of bestatin 10J.LM, captopril 1OJ.LM and thiorphan 
0.3J.LM. [n=3] 
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DISCUSSION 
Inclusion of the usual cocktail of enzyme inhibitors (bestatin, captopril and 
thiorphan) in the incubation medium stabilizes [Leu]enkephalin liberated from 
dynorphin 1-8 in addition to protecting the parent peptide as shown in Chapter 
3. These incubation conditions thus allow for the ready assessment of the 
enzymic activity responsible for the hydrolysis of the Leu5_Arg6 bond. 
Using competingsubstrates the optimum chain length for recognition by the 
enzymatic active site was seen to be between 8-13 amino acids. Indeed, 
dynorphin 1-13 displayed the most potent inhibitory action whilst dynorphin 1-
17 was completely inactive as were [Met] and [Leu]enkephalin. 
The production of [Leu]enkephalin from dynorphin 1-8 was not affected by the 
serine protease inhibitor phenylmethylsulphonylfluoride (PMSF) (ImM). It is 
therefore unlikely that the enzyme presently under investigation is a serine 
protease. Such an enzyme has been purified by Nyberg and colleagues from 
human cerebrospinal fluid [114]. This is of interest as it is able to hydrolyse the 
Arg6-Arg7 bond in dynorphin A and dynorphin B and the Arg6_Lys7 bond of 
alpha-neo-endorphin. 
However the enzyme studied in this thesis could be similar to a thiol protease 
purified from rat brain and designated endo-oligopeptidase A [18,19]. This 
enzyme is able to hydrolyse a variety of opioid pep tides. It reportedly liberates 
[Met]enkephalin from BAM-12P via cleavage of the Met5-Arg6 bond [15]. 
Similarly it is able to release [Leu]enkephalin fron dynorphin 1-8, dynorphin B, 
alpha-neoendorphin and beta-neoendorphin through cleavage between amino 
acid residues 5 and 6. Consistent with the results obtained here, more extended 
forms of opioid peptides are resistant to hydrolysis, dynorphin 1-17, peptide E, 
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peptide F and BAM-12P showing no detectable metabolism. In addition the 
peptides [Met] and [Leu]enlcephalin and the hexapeptide, [Leu]enlcephalyl-Arg6 
are resistant to hydrolysis. This agrees with the present studies in which the 
inability of these peptides to inhibit [Leu]enlcephalin production from dynorphin 
1-8 is observed. The four fold increase in inhibitory effect between 
[Leu]enlcephalyl-Arg6 and [Leu]enkephalyl-Arg6_Arg7 also correlates well with 
the reported properties of endo-oligopeptidase A. The heptapeptides . 
[Leu]enlcephalyl-Arg6_Arg7, [Met]enkephalyl-Arg6_Gly7 and [Met]enlcephalyl-
Arg6-Phe 7 are not converted to their respective pentapeptides by endo-
oligopeptidase A but are cleaved at the 4-5 bond releasing Tyr'-Gly2-Gly3-
Phe4• The octapeptide [Met]enlcephalyl-Arg6-Gly7-Leu8 is cleaved to give both 
[Met]enkephalin and Try'-Gly2-Gly3-Phe4 by purified endo-oligopeptidase A. 
Extension of [Met]enkephalyl-Arg6_Gly7-Leu8 by a single lysine residue results 
in [Met]enlcephalin being the sole metabolite. It is worth noting that in all cases 
where [Leu] and [Met]enlcephalin are formed, the enkephalin sequence is 
followed by a pair of basic amino acids. However the primary amino acid 
sequence of the petides is not alone in determining the cleavage site as the 
enzyme cleaves a variety of substrates; bradykinin, neurotensin and dynorphin 
B similarly well [16]. 
The lack of inhibitory potency of the metal chelators EDTA and Q-
phenanthroline again suggests the enzyme is similar to endo-oligopeptidase A, 
as it to is unaffected by EDTA [15], indicating the lack of an essential metal ion. 
The thiol blocking agents N-ethylmalemide (NEM) and p-
hydroxymercuribenzoate (n-HMB) caused a potent inhibition of 
[Leu]enlcephalin production. Again these results are consistent with thiol 
protease activity, the purified form of endo-oligopeptiase A being strongly 
inhibited by Il.-CMB [15]. However endo-oligopeptidase A is activated by 
dithiothreitol whereas the enzymatic activity responsible for the production of 
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[Leu]enkephalin in the present system is inhibited by dithiothreitol suggesting 
differences between the two enzyme systems. 
However a second enzyme has been reported that is also able to hydrolyse the 
Leu5_Arg6 bond of dynorphin 1-8. This enzyme was fIrst purified from the 
soluble fraction ofrat brain and designated EC 3.4.24.15, a zinc 
metalloendopeptidase. [118,119]. In addition to a soluble form, 20% of the 
enzymatic activity is tightly associated with synaptosomal membranes [1]. 
Unlike endo-oligopeptdase A, EC 3.4.24.15 is strongly inhibited by metal 
chelating agents such as EDTA, EGTA and Q-phenanthroline suggesting the 
presence of an essential metal ion. The lack of effect of EDTA in inhibiting the 
enzyme currently under investigation would appear to rule out the involvement 
of a metal ion. However this may not completely hold as EDTA is a relatively 
weak chelating agent, and therefore this enzyme may, like a variety of other 
enzymes, require dialysis against EDTA for several hours prior to any 
indication of inhibition of activity [162]. The variable response produced by Q-
phenanthroline is a better indication of the absence of an essential metal ion, 
especially considering Q-phenanthroline is also capable of inhibiting enzymatic 
activity in Krebs buffer. A purified form ofEC 3.4.24.15 displays a variable 
inhibition to thiol blocking agents, whereas the enzyme involved in the present 
metabolism is strongly inhibited by such compounds. However the site directed 
inhibitors ofEC 3.4.24.15 namely N-[(RS)-carboxy-2-phenylethyl]Ala-Ala-
Phe-pAB and N-[(RS)-carboxy-3-phenylpropyl]Ala-Ala-Phe-pAB [26,120] 
markedly reduce the level of recoverable rH][Leu]enkephalin in all tissues 
tested, whilst increasing the amount of intact [3H]dynorphin 1-8. Both 
inhibitors are effective against the soluble and membrane bound forms of the 
enzyme, preventing the hydrolysis of all the shorter opioid peptides to their 
respective pentapeptides and inhibiting the hydrolysis of other neuropeptides 
[1]. However the inhibitor N-[ -(RS)-carboxy-2-phenylethyl]Ala-Ala-Phe-pAB 
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appears to have no inhibitory effect against the ability of endo-oligopeptidase A 
to liberate [Leu]enkephalin from dynorphin 1-8 [154]. 
In spite of the apparent differences between endo-oligopeptidase A and EC 
3.4.24.15 there are a number of similarities. Both cleave the same bond within 
a variety of neuropeptides: neurotensin, bradykinin, dynorphin 1-8, alpha-
neoendorphin, beta-neoendorphin, BAM 12-P and [Met]enkephalyl-Arg6-
Gly7-Leu8• Larger peptides such as BAM 22P are resistant to hydrolysis as are 
the pentapeptides [Leu] and [Met]enkephalin and both enzymes hydrolyse 
alpha-neoendorphin at a substantially slower rate than that of beta-neoendorphin 
[116]. 
Whether or not two separate enzymes are responsible for the hydrolysis of the 
Leu5-Arg6 bond in dynorphin 1-8 is a matter of dispute. A recent publication 
suggests that only one enzyme is responsible for the production of 
[Leu]enkephalin from dynorphin 1-8 [154]. Both EC 3.4.24.15 and endo-
oligopeptidase A have sintilar molecular weights and are purified in the same 
manner. Following Sephadex G-l 00 gel filtration chromatography the two 
enzymes are contained within the same fraction. When a specific antibody, 
raised against endo-oligopeptidase A, is used to remove endo-oligopeptidase A 
activity within this ntixed fraction, the remaining enzyntic activity is unable to 
hydrolyse dynorphin 1-8 or metorphamide to [Leu]enkephalin. However, the 
remaining enzymic activity is able to hydrolyse the synthetic substrate of 
EC 3.4.24.15 namely Bz-Gly-Ala-Ala-Phe-pAB, a hydrolysis that was 
inhibited by N-[(RS)-carboxy-3-phenylpropyl]Ala-Ala-Phe-pAB, indicating the 
presence of EC 3.4.24.15. This coupled with the observation that the activity 
accorded to EC 3.4.24.15 displayed a variable inhibition to thiol blocking 
agents [1.119] suggests that the ability to hydrolyse dynorphin 1-8 to 
[Leu]enkephalin was the result of contamination with endo-oligopeptidase A. 
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Futher anomalies are also evident in the present study. The lack of effect of 
EDTA questions the involvement of an essential metal ion. However this result 
is not conclusive as chelating agents vary in their efficacy to remove metal ions 
from proteins and often long periods of incubation are needed [162]. Likewise 
although the inhibitory properties of the thiol reagents NEM and nHMB are 
marked suggesting the involvement of a thiol protease such as endo-
oligopeptidase A a definite assignment cannot be made considering endo-
oJigopeptidase A is activated by dithiothreitol [18] whereas in the present study 
dithiothreitol is inhibitory. In addition, the inhibitory action of the thiol reagents 
such as NEM of n-HMB can be ascribed to non-thiol interactions. Certainly 
NEM is not specific for thiols and will alkylate lysine and histidine residues 
whereas n-HMB may act non-specifically [85,86]. It is, therefore, very difficult 
to ascertain which of the two enzymes is responsible for the hydrolysis of 
dynorphin 1-8 to [Leu]enkephalin. Indeed in the light of the work carried out by 
Toffoletto and colleagues, who demonstrated the presence of both enzymes in 
the same fraction of rat brain it is possible that the observations described above 
are the result of both metallo- and thiol-protease activity. 
CHAPTER 5 
Isolated Tissue Studies 
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INTRODUCTION 
In the light of the results presented in the previous two chapters it appears that 
dynorphin 1-8 is widely and efficiently metabolised to [Leu]enkephalin via a 
direct hydrolysis of the Leu5-Arg6 bond by one or more enzymes. This 
hydrolysis can therefore be viewed as a conversion process rather than a 
metabolic inactivation since it generates a bioactive molecule. It is important 
therefore to investigate the effect of such metabolism on the agonist activity of 
dynorphin 1-8 in a functional assay. The myenteric plexus longitudinal muscle 
(MPLM) preparation of the guinea-pig provides an ideal tissue with which to 
examine the conversion of dynorphin 1-8 to [Leu]enkephalin. The MPLM of 
the guinea-pig contains only functional kappa and mu receptors and does 
metabolise dynorphin 1-8. This tissue will therefore allow the effect of the 
conversion of the kappa preferring dynorphin 1-8 to the delta/mu (in the case of 
the MPLM mu) preferring [Leu]enkephalin to be monitored. 
The ability of dynorphin 1-8 to inhibit the electrically evoked contractions of the 
guinea-pig MPLM may be investigated using the octapeptide in the presence of 
various enzyme inhibitors. Construction of full Schild plots using various 
antagonists and agonists will ascertain which opioid receptor type is responsible 
for the inhibition of the twitch under all enzyme inhibitor conditions. It is hoped 
that the results obtained will provide preliminary information concerning what, 
if any, role is played by the conversion of dynorphin 1-8 to [Leu]enkephalin. 
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RESULTS 
1.) Naloxone as antagonist 
Dynorphin 1-8 caused a dose dependent inhibition of the electrically evoked 
contractions of the myenteric plexus longitudinal muscle (MPLM) of the guinea-
pig ileum [Fig. 5.1]. The concentration of dynorphin 1-8 required to produce a 
50% inhibition of contraction (IC50) was 27.4 ± 3.7nM. Pre-incubation of the 
MPLM with varying concentrations of the opioid antagonist naloxone prior to 
addition of dynorphin 1-8 shifted the dynorphin 1-8 dose response curve to the 
right. From this data a dissociation constant (Ke) for the antagonist of 
14.03 ± 2.4nM obtained from the Schild plot, with a slope of unity [Fig. 5.2] 
could be calculated. 
The enzyme inhibitor cocktail of best at in, IOIlM; captopril, 10llM and thiorphan 
O.3iJM was added to the bath for 30min, to reduce peptidase activity, prior to 
repeating the dynorphin dose response curve. The 1C50 of dynorphin 1-8 
decreased to 1.8 ± O.4nM under these conditions. When the effects of 
naloxone against the agonist activity of dynorphin 1-8 were studied in the 
presence of the peptidase inhibitory cocktail a concomitant decrease in the value 
of the naloxone Ke to 3.01 ± 0.79nM was observ~d. However the slope of the 
corresponding Schild plot decreased to 0.86 ± 0.08, a value significantly less 
than unity (P<0.05) [Fig. 5.3]. 
The non-labile mu opioid receptor agonist DAGOL was effective at inhibiting 
the electrically evoked contractions of the MPLM affording an 1C50 of 15.2 ± 
O.lnM. Repetition of the dose response to DAGOL in the presence of 
increasing concentrations of naloxone resulted in a shift of the dose-response 
curve to the right. Determination of the Schild plot from this data gave a Ke of 
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2.09 ± 0.54nM [Fig. 5.4] with a slope of unity. In contrast to dynorphin 1-8 a 
30min preincubation with the enzyme inhibitory cocktail failed to alter either the 
naloxone Ke 3.07 ± 0.82nM or the IC50 21.3 ± 7.4nM ofDAGOL in this 
tissue. Indeed the value of the naloxone Ke obtained using the agonist DAGOL 
was not significantly different to that obtained using dynorphin 1-8 as agonist in 
the presence of the cocktail of enzyme inhibitors. Likewise, the naloxone Ke 
(1.63 ± 0.34nM) obtained using [Leu]enkephalin as agonist [Fig. 5.5], in the 
presence of the enzyme inhibitor cocktail, does not differ significantly from the 
Ke obtained with either DAGOL or dynorphin 1-8 in the presence of peptidase 
inhibition. 
A 30min preincubation of the MPLM with the site directed inhibitor of EC 
3.4.24.15, namely N-[ -(RS)-carboxy-2-phenylethyl]-Ala-Ala-Phe-pAB 
(30~M) and the inhibitor cocktail of bestatin, 1OJ.1M; captopril, lO~M and 
thiorphan, O.3IlM prior to assaying dynorphin 1-8, did not significantly change 
the IC50 value of dynorphin 1-8 as compared with the IC50 value of the 
octapeptide obtained in the presence of the inhibitory cocktail alone. However 
under these inhibitory conditions a single dose of naloxone led to a shift to the 
right of the dose response curve to dynorphin 1-8. From this single dose 
response curve a single dose Ke [179] was calculated. Under these inhibitory 
conditions an increase in the naloxone Ke of dynorphin 1-8 from 
3.01 ± O.79nM to 14.31 ± 2.1nM in the absence and presence respectively of 
the inhibitor N-[-(RS)-carboxy-2-phenylethyl]-Ala-Ala-Phe-pAB (30IlM) was 
observed. Replacing N-[-(RS)-carboxy-2-phenylethyl]-Ala-Ala-Phe-pAB in the 
inhibitory cocktail with the more potent inhibitor N-[ -(RS)-carboxy-3-
phenylpropyl]-Ala-Ala-Phe-pAB (O.3IlM) increased further the naloxone Ke 
against dynorphin 1-8 to 37.2 ± 8.3nM. The slope of the corresponding 
Schild plot was unity [Fig. 5.6]. Inclusion of the E.C. 3.4.24.15 inhibitor N-[-
(RS)-carboxy-2-phenylethyl]-Ala-Ala-Phe-pAB (30IlM) in the inhibitory 
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cocktail afforded a naloxone Ke calaculated against the mu agonist DAGOL of 
3.0 ± 0.6nM a value not significantly different to the naloxone Ke calculated in 
the absence ofN-[-(RS)-carboxy-2-phenylethyl]-Ala-Ala-Phe-pAB. 
Similarly the less labile opioid peptide, dynorphin 1-17, used in the absence of 
peptidase inhibitors, afforded a naloxone Ke of 33.6 ± 1.02nM with a SchiId 
plot of slope unity [Fig. 5.7]. In addition using the stable kappa preferring U69 
593 as agonist a naloxone Ke of 31.4 ± 9.69 nM, again with SchiId plot slope 
of unity was obtained [Fig. 5.8]. The Ke values and the slope of the SchiId 
plots for U69 593 and dynorphin 1-17 do not significantly differ from those 
values obtained using dynoqihin 1-8 in the presence of the inhibitor cocktail and 
N -[ -(RS )-carboxy-3-pheny Ipropy 1]-Ala-Ala-Phe-pAB. 
2.) Nor-Binaltorphimine (nor-BN!) as antagonist 
Using the kappa receptor prefening nor-BNI to antagonise the agonist effects of 
dynorphin 1-8 in the MPLM a Schild plot could be constructed which afforded 
a Ke value of 0.17 ± 0.04nM and a slope of unity [Fig. 5.9]. In the presence 
of the inhibitor cocktail of, bestatin 101lM; captoprill O!J.M and thiorphan 
0.3!J.M, the Ke of dynorphin 1-8 against nor-BNI significantly increased 
(P<0.05) to 0.62 ± 0.07nM, the slope of the SchiId plot remained unity 
[Fig. 5.10]. When used as antagonist against the mu ligand DAGOL the Ke 
was 13.03 ± 1.91nM, the slope of the Schild plot remained close to unity 
[Fig. 5.11]. 
In the presence of both the inhibitor cocktail and N-[-(RS)-carboxy-3-
phenylpropyl]-Ala-Ala-Phe-pAB (0.3IlM), preincubated for 30min prior to the 
addition of agonist, a Ke for nor-BNI detennined against the agonist effects of 
dynorphin 1-8 of 0.098 ± 0.047nM with a slope of 0.99 ± 0.12 was 
found[Fig. 5.12]. Similarly when the agonist U69 593 was used, in the 
absence of peptidase inhibitors, a low Ke value of 0.067 ± 0.03nM and a 
slope of unity were obtained [Fig. 5.13]. 
3.) MSOOS (J6methylcyprenorphine) as antagonist 
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The Schild plot ofM8008 using dynorphin 1-8 as agonist afforded a Ke of 
76.9 ± l1.1nM, with a Schild plot slope of unity [Fig. 5.14]. The addition of 
the inhibitor cocktail of, bestatin 101lM; captoprillOllM and thiorphan 0.31lM 
to the tissue 30min prior to the addition of dynorphin I-S decreased the Ke 
against M800S to 31.4 ± 8.8nM, the slope of the corresponding Schild plot 
was significantly less than unity [Fig. 5.15]. Using the mu receptor preferring 
agonist DAGOL the Ke obtained for MSOOS was 3.5 ± 1.2nM from a Schild 
plot with a slope of unity [Fig. 5.16]. 
Addition of the potent inhibitor N-[-(RS)-carboxy-3-phenylpropyl]-Ala-Ala-
Phe-pAB (0.3IlM) to the standard inhibitor cocktail resulted in a large increase 
in the Ke of M800S as measured against dynorphin I-S to 208.5 ± 70.3nM, 
again the slope of the Schild plot did not differ from unity [Fig. 5.17]. 
Similarly the agonist U69 593 afforded a high Ke value of S5.S ± 14.4nM, 
with a Schild plot slope of unity [Fig. 5.18]. 
-I 
By :malysis ofvarianc; (ANOVAfollowed by Dunnett's test) non of the dose response curves I 
deVlatedfrom paralleli~. All ScJri1d plot slopes did not differ significantly from unity, except : 
where stated (Mann Wltitney U). Each concentration of antagonist produced a significant . 
(P<O. 05 ANOVA, Dunnettt's test) increase in the lO"o value oft1Je t1Je agonist compared to t1Je • 
lO"o value obtained in t1Je presence oft1Jeprevious dose of antagonist. I 
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4.) Irreversible alkylation o/the mu-receptors in MPLM by beta-junaltrexamine 
i.) Standard Compounds 
The mu selective agonist DAGOL was used as a marker to test for successful 
alkylation. If the ratio of ICso values determined from the dose response curves 
for DAGOL before and after treatment with lOOnM beta-funaltrexamine (beta-
FNA), incubated with the tissue for lhour followed by a minimum of lhour 
washout, was less than 20 the experiment was discarded. 
As can be seen from Table 5.1 the mean dose ratio for DAGOL was 
26.1 ± 7.49. In contrast the ICso for the kappa selective agonist U50 4SSH 
was essentially unaffected by beta-FNA treatment affording a dose ratio of 
2.1 ± 0.2. The dose response curve to the pentapeptide [Leu]enkephalin, in 
the presence of the same inhibitor cocktail, was greatly affected by beta-FNA 
treatment displaying a dose-ratio of 15.9. 
ii.) Dynorphin 1-8 
The potency of dynorphin I-S to inhibit the MPLM was unaffected by beta-
FNA alkylation, affording a dose-ratio of 0.61 ± O.OS. However, upon the 
addition of the enzyme inhibitor cocktail of bestatin, 101lM; captopril, 10!J.M 
and thiorphan, O.3IlM, the ICso after alkylation shifted to the right affording a 
dose-ratio of 1.57 ± 0.27, a value not significantly different to that of 
uninhibited dynorphin l-S. Inclusion of the site directed inhibitor N-[ -(RS)-
carboxy-3-phenylpropyl]-Ala-Ala-Phe-pAB (0.3IlM) in the inhibitor cocktail 
significantly reduced (P<0.05) the dose-ratio of dynorphin I~S to O.SO ± 0.05 
again this value is not significantly different to that obtained using dynorphin I-
S in the absence of any peptidase inhibition. 
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Figure 5.1 : Inhibition of the elecnically induced contractions of the myenteric 
plexus longitudinal muscle of the guinea-pig by dynorphin 1-8 (upper rrace) and 
dynorphin 1-8 in the presence of bestatin, lO~M; captopril, lO~M and thiorphan, 
O.3~M (lower rrace). Numbers are concentration of dynorphin 1-8 (nM). 
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Figure S.2 : Inhibition of electrically induced contractions of the myenteric plexus longitudinal muscle of the guinea-pig by dynorphin 1-8 in the abscence 
(e) and in the presence of SOnM (.). SOOnM ( .... ) and SOOOnM (0) naloxone. Sample of a corresponding Schild plot (.) shown on the right. 
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Figure 5.3 : Inhibition of electrically induced contractions of the myenteric plexus longitudinal muscle of the guinea-pig, in the presence of bestatin, lO~M; 
captopril, lO~M and thiorphan, O.3~M by dynorphin 1-8 in the abscence (e) and in the presence of 50nM (B), IOOnM (4) and 500nM (0) naloxone. 
Sample of a corresponding Schild plot (B) shown on the right. . 
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and in the presence of 50nM CB), lOOnM C ... ) and 500nM CO) naloxone. Sample of a corresponding Schild plot Ca) shown on the right. 
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Figure 5.17 : Inhibition of elecoically induced contractions of the myenteric plexus longitudinal muscle of the guinea-pig, in the presence of bestatin, 
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DISCUSSION 
The increase in potency (measured as a decrease in the-ICso value) of dynorphin 
1-8 in the MPLM upon the addition of peptidase inhibitors indicates a 
stabiIization of the dynorphin molecule. This phenomenon has been widely 
reported, occurring in a variety of tissues including the mouse and rabbit vas 
deferens, in addition to the MPLM of the guinea-pig [28,84,130,133]. However 
the effect of peptidase inhibition on the naloxone Ke against dynorphin 1-8, 
calculated using the Schild plot technique, had not been previously investigated. 
Such studies with naloxone as antagonist are essential to define the receptor 
population at which the agonist is exerting its effect. Earlier studies revealed 
naloxone whilst not ideal, to be an antagonist capable of clearly distinguishing 
mu from kappa receptors in the MPLM of the guinea-pig ileum [82,96]. 
Calculation of naloxone Ke values against agonists at the mu and kappa receptor 
population in the MPLM fall within the ranges of <5 and > 14nM respectively 
[82,96]. In addition using the SchiId plot method to calculate antagonist Ke 
values also indicates whether the agonist is able to displace the antagonist from 
more than one receptor type. Schild plot slopes of less than unity indicate an 
interaction with more than one receptor type. 
Single dose Ke values for dynorphin 1-8, obtained in both the absence and 
presence of peptidase inhibitors had been reported by James and co-workers 
[84]. These workers observed a decrease in the naloxone Ke against dynorphin 
1-8, in guinea-pig MPLM, from 15 ± 1.5nM to 8.3 ± .07nM upon the 
addition of 10JlM bestatin; lOJlM captopril; O.3JlM thiorphan and 2mM leucyl-
leucine. This decrease in the naloxone Ke, after peptidase inhibition broadly 
agrees with the results obtained in this thesis. However in the discussion' of 
their findings they conclude that the inclusion of peptidase inhibitors did not 
significantly change the naloxone Ke, its value remaining at an intermediate 
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level between that expected for an interaction at mu or kappa receptors and is in 
line with the un selective nature of dynorphin 1-8 [28]. However because only 
the single dose method was used to calculate the naloxone Ke in the previous 
work it was not possible to tell whether one or more receptor types were 
involved. The decrease obtained in the present studies was however, greater in 
magnitude, the naloxone Ke decreasing from 14nM, in the absence of 
inhibitors, to 3nM in the presence of peptidase inhibitors, suggesting a change 
in receptor preference profile from kappa to mu . 
Considering that in the results presented in this chapter the Ke value of 
• dynorphin 1-8, in the presence of peptidase inhibitors, against naloxone does 
not differ from that obtained using DAGOL it would appear that dynorphin 1-8, 
in the presence of the inhibitor cocktail, is able to interact with the mu receptor 
population within the MPLM of the guinea-pig. As demonstrated in Chapter 3 
the MPLM is able to metabolise [3H]dynorphin 1-8 to rH][Leu]enkephalin. It 
is therefore possible that the Ke value obtained in the presence of inhibitors is a 
result of dynorphin 1-8 being metabolised to [Leu]enkephalin which 
subsequently activates the mu receptor population. This theory is further 
supported by the naloxone Ke value obtained using inhibited [Leu]enkephalin 
as agonist, affording a value that does not differ from those obtained using 
either DAGOL or inhibited dynorphin 1-8. The interferance of delta receptor 
occupation can be ruled out as the MPLM of the guinea-pig ileum contains only 
functional mu and kappa receptors [21, 96]. 
Addition of the site directed inhibitor of EC 3.4.24.15, namely N-[ -(RS)-
carboxy-2-phenylethyl]-Ala-Ala-Phe-pAB [26] to the enzyme inhibitor cocktail 
resulted in an increase in the naloxone Ke of the dynorphin 1-8 to a value not 
dissimilar to that obtained using dynorphin l-S in the absence of any peptidase 
inhibitors and within the range associated with interaction with a kappa receptor 
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population. Unfortunately lack of availability of the inhibitor only allowed for 
the use of the single dose Ke method. Substituting the more potent N·[ ·(RS)· 
carboxy·3·phenylpropyl]·Ala·Ala·Phe·pAB for the more potent N·[·(RS)· 
carboxy·Z·phenylethyl]·Ala·A1a·Phe·pAB [120] in the inhibitor cocktail 
increased further the naloxone Ke against dynorphin 1·8 to a value not 
significantly different to the Ke values obtained against the kappa preferring 
ligands U69 593 [89] and dynorphin 1·17 [84]. Results reported in Chapter 4 
have shown that inclusion ofN·[-(RS)·carboxy·3·phenylpropyl]·Ala·Ala·Phe· 
pAB in the inhibitor cocktail almost completely protects the dynorphin 1·8 
molecule from degradative attack. It would appear therefore that intact 
dynorphin 1·8 is selective for the kappa opioid receptor under these conditions. 
Use of the kappa preferring antagonist nor·BNI [127, 150] again highlights the 
selectivity of dynorphin 1·8, when correctly stabilized, for the kappa receptor. 
Previously reported Ke values for nor·BNI range from O.1nM to O.OOSnM [12] 
measured against USO 488H or ethylketocyclazocine as kappa selective ligands. 
The more selective kappa agonist U69 593, as used in the present study 
afforded Ke values within this range, as did dynorphin 1·8 in the presence of 
the usual inhibitor cocktail plus N·[·(RS)·carboxy·3·phenylpropyl]-Ala-Ala-
Phe-pAB. The uninhibited octapeptide displayed a higher Ke value outside this 
range. Birch and co·workers using DAGOL as agonist obtained Ke values 
ranging from 50.1nM to O.8nM: The results obtained here for DAGOL were 
within this range although with a much smaller variation. Dynorphin 1-8 in the 
presence of the inhibitor cocktail afforded a Ke value just outside the lower end 
of the range previously reported, but again with a far smaller standard error. All 
Schild plots had slopes of unity indicating the high selectivity ofnor·BNI for 
the kappa receptor. 
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The large standard errors obtained by Birch and colleagues could be the result 
of insufficient antagonist equilibration time. This would result in large errors in 
the estimate of Ke values. In the present study using U69 593 as agonist, a 
concentration of O.3nM nor-BNI required a minimum of 30min preincubation 
in order to obtain equilibrium. The lower concentration of O.lnM nor-BNI, 
incubated for 30min, used by Birch would therefore require a longer incubation 
period. In order to be confident that complete equlibrium conditions were 
obtained a 45min incubation period was used throughout each Schild plot, even 
when higher concentrations of nor-BNI were used. 
Previous studies have shown M8008 to be a pure antagonist at opioid receptors 
that displays a preference for mu and delta over kappa receptors. However, 
considering the MPLM of the guinea-pig contains only mu and kappa receptors 
[22] any delta receptor affinity displayed by M8008 is irrelevant in this tissue. 
M8008 is able therefore to distinguish between mu and kappa receptors 
displaying a kappa/mu selectivity ratio of 33.6 in the mouse vas deferens [144]. 
A Ke for M8008 against uninhibited dynorphin 1-8 of76.9 ± ll.1nM, 
indicative of an action at a kappa receptor population was determined. This 
kappa Ke value for M8008 is substantially greater than those previously 
published. Using the kappa agonist ethylketocyclazocine (EKe) which afforded 
a Ke of33.1nM in MPML [144] Smith obtained the highestreported kappa Ke 
value of 62.4 ± 18nM in the rabbit vas deferens using ethylketocyclazocine as 
agonist. The kappa selective agonist U69 593 also afforded a Ke value greater 
than any previously reported. Whilst the mu preferring agonist DAGOL gave a 
low value Ke somewhat more in line with data published by Smith who 
obtained a Ke of 0.65 ± O.05nM using normorphine as agonist. 
The addition of the enzyme inhibitor cocktail decreased the Ke of dynorphin 1-8 
to 31.4nM, a value that correlates well with that previously published using 
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EKe as agonist. However the slope of the corresponding Schild plot was less 
than unity, indicating an action at more than one receptor type. Addition of the 
inhibitor N-[-(RS)-carboxy-3-phenylpropyl]-Ala-Ala-Phe-pAB increased the 
Schild plot slope to unity and increased the Ke to 208 ± 70.3nM a value far in 
excess of previously published data in a wide variety of tissues [144]. These 
results confirm dynorphin 1-8 as a kappa preferring ligand which, when 
correctly stabilized, displays an increased potency and an apparent increase in 
selectivity towards the kappa receptor. In addition it would appear that in the 
present studies the antagonist M8008 may have a higher kappa/mu selectivity 
ratio than previously reported. 
The ability of dynorphin 1-8 in the presence of the inhibitor cocktail to interact 
with the mu receptors, within the MPLM, through its metabolism to the 
pentapeptide [Leu]enkephalin could be further revealed using the mu selective 
alkylating agent beta-FNA. Previous studies have shown beta-FNA to be lOO 
times more selective for mu over kappa receptors [60]. Indeed beta-FNA is an 
agonist at kappa receptors and an antagonist at mu receptors Treatment with 
beta-FNA failed to elicit a shift in the dose-response curve to the kappa selective 
U 50 488H. The dose response curves to uninhibited dynorphin 1-8 and 
dynorphin 1-8 in the presence of the inhibitor cocktail and N-[-(RS)-carboxy-3-
phenylpropyl]-Ala-Ala-Phe-pAB were also unaffected by beta-FNA treatment. 
These results are indicative of an interaction with a kappa receptor population 
following the selective alkylation of the mu receptors within the MPLM which 
had been achieved as indicated by the large shift in the IC50 ofDAGOL. 
Similarly [Leu]enkephalin, in the presence of the peptidase inhibitors suffered a 
large decrease in potency after beta-FNA treatment. Dose response curves 
constructed for dynorphin 1-8 in the presence of the inhibitor cocktail were 
displaced to the right, however this displacement failed to produce shifts in dose 
responses folIowing beta-FNA that were significantly different to those 
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obtained for USO 488H, uninhibited dynorphin 1-8 and inhibited dynorphin 1-8 
in the presence ofN-[-(RS)-carboxy-3-phenylpropyl]-Ala-Ala-Phe-pAB. 
These results indicate that a proportion of the response caused by inhibited 
dynorphin 1-8 is afforded through conversion to [Leu]enkephalin which then 
interacts with the mu receptor population. However sufficient dynorphin 1-8 
remains intact to allow for the activation of kappa receptors, when the mu 
receptor population is severely reduced following beta-FNA alkylation. 
CHAPTER 6 
Ontogenic Development of the Enzyme Responsible for the 
Hydrolysis of the Leu5.Arg6 bond within [3H]Dynorphin 1·8 
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INTRODUCTION 
It is well known that both opioid receptor density [Hl6] and opioid peptide levels 
[106] increase from birth to adulthood. The ratios of the various opioid 
prohormone products also vary with age [177]. Little work however has been 
carried out on the ontogenic development of the enzymes responsible for the 
metabolism ofnenropeptides [177]. General studies investigating the changes in 
aminopeptidase and enkephalinase (the enzyme responsible for cleaving the 
Gly3-Phe4 bond within the pentapeptides) have been carried out [122]. However 
no study has traced the development of either endo-oligopeptidase A or EC 
3.4.24.15. If these enzymes play an important role in the metabolism of 
dynorphin 1-8 and the consequent conversion of the octapeptide to 
, , 
[Leu]enkephalin has an important physiological function, it is possible to 
speculate that the development of the enzyme responsible for this conversion 
should be related to the ontogeny of the opioid pep tides and their receptors 
within the C.n.S. 
This chapter investigates the ontogenic development of the production of 
dynorphin 1-8 to [Leu]enkephalin and relates this development to the ontogeny 
of both opioid receptors and opioid peptide levels within the matnring rat c.n.s. 
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RESULTS 
In order to examine the ontogenic development of the enzyme responsible for 
the release of rH][Leu]enkephalin fron [3H]dynorphin 1-8 the following 
experiments were all performed in the presence of the peptidase inhibitor 
cocktail (bestatin 1OJ.1M; captoprill0J.1M and thiorphan 0.3J.1M) to allow the 
measurement of [3H][Leu]enkephalin production as discussed in previous 
chapters. 
Slices of spinal cord from 1 day old rats were able to release 
[3H] [Leu]enkephalin from [3H]dynorphin 1-8. Following a lOmin incubation 
period at 37°C 32.3 ± 1.7% of recovered radioactivity co-eluted with the 
[Leu]enkephalin marker peptide [Fig 6.1]. The largest portion of radioactivity, 
67.7 ± 1.7%, co-eluted with the dynorphin 1-8 marker peptide. Little 
aminopeptidase activity remained in the presence of the inhibitors as the N-
terminal fraction accounted for only 2.4 ± 2.4% of the recovered radioactivity. 
The level of [3H]dynorphin 1-8 recovered following a lOmin incubation 
decreased sharply from day 1 until day 7, when it reached a value of 
28.5 ± 6.5%. The metabolism had then reached a plateau that remained until 
day 14. However from day 14 the level of rHldynorphin 1-8 continued to 
decline reaching 11.9 ± 5.3% by day 21. This increased metabolism of 
[3H]dynorphin 1-8 corresponded to a peak in measurable aminopeptidase 
activity. An increase in the amount of N-terminal fraction accounting for 
36.3 ± 11.9% of recovered radioactivity, even in the presence of the 
aminopeptidase inhibitor bestatin (lOIlM) was found. However, this peak of 
aminopeptidase activity decreased by day 28 to astable level of 12.6 ± 2.2%. 
The level of rH] [Leu]enkephalin rose steadily as the level of rH]dynorphin 1-
8 decreased, reaching a peak at day 10 accounting for 59.6 ± 8.8% of 
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recovered radioactivity. This level of [3H][Leu]enkephalin was maintained until 
day 28 when at 56.3 ± 2.5% the level began to increase reaching 
65.7 ± 3.0% at day 56. 
!Q. 
This pattern of metabolism displayed by the spinal cord was closely paralle,(i by 
the cortex. Again as early as day I after birth cortex tissue was able to liberate 
[3H][Leu]enkephalin from [3H]dynorphin 1-8. After a 10min incubation at 
37°C [3H][Leu]enkephalin and [3H]dynorphin 1-8 accounted for 30.4 ± 4.5% 
and 74.0 ± 1.1% of the recovered radioactivity respectively [Fig 6.2]. The 
presence of the inhibitor cocktail of, bestatin lOJlM; captoprillOJlM and 
thiorphan 0.3JlM, completely prevented the degradation of the N -terminal at day 
I in cortex tissue. However, aminopeptidase activity overcame this inhibition 
and was evident at day 21 when the N-terminal fraction accounted for 
34.6 ± 16.8% of eluted radioactivity even after the supposed inhibition of 
aminopeptidases. As in spinal cord tissue, this peak in aminopeptidase activity 
corresponded to a trough in the level of recoverable [3H]dynorphin 1-8 which 
dropped to 15.7 ± 1.7%. This level of recoverable [3H]dynorphin 1-8 then 
increased to reach a stable value of 32.4 ± 3.1 % at day 28, this level was 
unchanged on day 56 at 29.2 ± 4.7%. The amount of recoverable 
[3H][Leu]enkephalin steadily increased with age reaching a peak at day 7 
accounting for 57.7 ± 1.2% and 48.1 ±7.93 on day 14. The level of 
[3H][Leu]enkephalin produced began to increase from day 14 reaching 
60.5 ± 4.3% on day 56. 
Striatal tissue, from 1 day old rats was also able to produce 
[3H][Leu]enkephalin (31.7%) from exogenous [3H]dynorphin 1-8 [Fig 6.3]. 
The level of pH]dynorphin 1-8 rernaining decreased slowly from an initial 
value of 65.4% at day 1 to 13.2 ± 4.1 % at day 21, thereafter rising to 
27.1 ± 4.0% by day 56. The lowest level of [3H]dynorphin 1-8 occurring at 
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day 21 corresponded to the highest level ofrecoverable N-tenrunal fraction at 
38.7 ± 9.9%. This peak in aminopeptidase activity also paralleled the trough in 
the level of [3H][Leu]enkephalin (46.3 ± 4.4%), which reached its peak value 
at day 10 accounting for 62.4 ± 5.8% of the recovered radioactivity. The 
amount ofrecoverable [3H][Leu]enkephalin rose from day 21 to day 28, 
thereafter maintaining a steady value between 55 to 69 percent. 
The pattern of metabolism produced by the cerebellum was somewhat different 
to that displayed by the spinal cord, cortex and striatum. Again the level of 
recoverable [3H]dynorphin 1-8 decreased steadily from day 1 (74.0± 1.1%) 
to day 21 (14.4 ± 10.1 %). displaying a plateau phase between day 7 and day 
14, when the level remained at approximately 30% [Fig 6.4]. After day 21 the 
amount of [3H]dynorphin 1-8 began to increase back to the 30% level. In this 
case the trough in the level of recoverable [3H]dynorphin 1-8 was not 
accompanied by an increase in aminopeptidase activity, which reached a 
maximum on day 14 represented by the high level ofN-tenrunal fraction 
recovered (33.6 ± 10.1 %). The peak in aminopeptidase activity, at day 14, 
was paralleled by a sharp decrease in recoverable [3H][Leu]enkephaJin which 
contributed only 37.6 ± 2.8% to the total recovered radioactivity. The highest 
level of [3H][Leu]enkephalin was recorded on day 21 (63.1 ± 1.9%) 
corresponding to the lowest level of [3H]dynorphin 1-8, this level of 
[3H][Leu]enkephalin was maintained until day 56. 
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DISCUSSION 
It would appear from the results described above that aminopeptidase activity at 
postnatal day 1 in all four areas investigated is a bestatin sensitive 
aminopeptidase as inclusion of the aminopeptidase inhibitor bestatin in the 
incubation medium completely inhibits the cleavage of the N-terminus of 
dynorphin I-S. A previous study reported aminopeptidase activity at birth, with 
only a two fold increase in activity in the adult rat [106]. However the ontogenic 
development of the total aminopeptidase activity, as measured by Patey and co-
workers could differ from the ontogenic development of any bestatin resistant 
aminopeptidase measured in this study. Alternatively the amount of bestatin 
present in the incubation medium may be sufficient to inhibit the lower levels of 
aminopeptidase present at birth but is not sufficient to totally block the cleavage 
of the N-terminal tyrosine of dynorphin I-S as the levels of aminopeptidase 
increase with age. 
The level of recoverable dynorphin I-S displays a steady decrease from birth to 
adulthood, and all C.n.S. regions studied are able to liberate [Leu]enkephalin as 
early as , post-natal day 1. Since [Leu]enkephalin may be the endogenous 
ligand at the delta receptor it is important to compare these fmdings with the 
ontogeny of delta receptors. However these findings contrast with the ontogeny 
of the delta opioid receptor. Using the delta selective ligand [D-Pen2,o-
Pen5]enkephalin, delta receptors cannot be detected before post-natal day 10, 
with peak binding seen at day 25 [106]. However [Leu]enkephalin also has a 
high affinity for mu receptors and mu binding sites are present as early as post-
natal day 1 [146], although the numbers decline for several days after birth, 
prior to increasing to adult levels within two weeks. Spain and co-workers 
[146] also report an increase in delta receptor binding after post-natal day 10 
which corresponds to a peak in [Leu]enkephalin production seen in all four 
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c.n.s. regions. The rat c.n.s. is, therefore, able to produce [Leu]enkephalin 
before the development of substantial delta-binding sites for [Leu]enkephalin. 
However the early peak in the enzyme activity that liberates the pentapeptide 
from dynorphin 1-8 corresponds to the start of an increase in both delta and mu 
receptor binding capacities. 
Kappa receptor binding capacity is low at birth and only increases twofold in 
the adult rat [146]. However using [3H]ethylketocyclazocine, with binding to 
mu and delta suppressed as the kappa ligand, identifies two binding sites, one 
of very low affinity. This could explain the discrepancies found between 
laboratories where different studies have revealed peak kappa binding to occur 
as early as day 16 [8] or as late as day 35 [146]. The development of kappa 
binding does not therefore appear to be related to the development of dynorphin 
1-8 metabolism. However, as the ratio of [Leu]enkephalin to dynorphin 1-8 
increases with age so does the ratio of delta/kappa receptors, as the increase in 
the level of delta receptor binding is more pronounced than that of kappa 
receptor binding [146]. Kappa receptors also display a differential development 
pattern in the fore and hind (cerebellum and brain stem) brain areas. Initial 
densities are the same in both brain areas, however, hindbrain levels rise 
substantially until day 14 when they begin to decline as fore brain levels increase 
[146]. This rostral to caudal development is seen in other opioid receptor 
development [29, 156]. 
The levels of all opioid peptides within the c.n.s. increase from birth to adult 
animals [139, 177]. Zamir and co-workers reported the main increase in levels of 
proenkephalin and prodynorphin derived peptides in rat hippocampus occurs 
during the period from post-natal day 7 to day 14 when dynorphiit A, 
dynorphin 1-8, dynorphin Band alpha-neoendorphin reach adult levels. Again 
this period corresponds with the peak in enzymatic activity liberating 
[Leu]enkephalin from dynorphin I-S . 
79 
The ratio of dynorphin 1-17 to dynorphin I-S in the neurointennediate lobe of 
the pituitary in neonates is 3:1 whereas in the adult the levels of the two peptides 
are equal. It would appear therefore, that the enzyme responsible for cleaving 
the single arginine residue in dynorphin 1-17 to liberate dynorphin I-S is not 
fully developed at birth [139]. In addition, a decrease in the concentration of 
immunoreactive dynorphin I-S recovered from the neurointennediate pituitary 
of the rat is seen at post-natal day 7 [139], with no corresponding decrease in the 
concentration of dynorphin 1-17. This decrease in dynorphin I-S could be 
explained by an increase in enzyme activity seen to occur at day 7 in brain and 
spinal tissue resulting in an increased metabolism of dynorphin I-S to 
[Leu]enkephalin. Seizinger [139] also reported an increase in [Leu]enkephaJin 
content in the anterior pituitary from birth to adulthood but unfortunately did not 
measure the level of dynorphin I-S in this area. 
The development of enkephalin levels in the c.n.s. proceeds in a caudal to 
rostral direction, in a similar manner to the observed development in opioid 
receptor binding. Peak enkephaJin levels are seen within the fust week of 
development in the cerebellum, the second week in the brains tern and the third 
week in the forebrain [156]. This caudal to rostra! development is not seen in the 
present study of the liberation of [Leu]enkephalin from dynorphin I-S. 
However, other studies have described more consistent general increases in 
enkephalin levels across all brain regions [13]. 
It would appear therefore that in general the ontogeny of the enzyme responsible 
for the liberation of [Leu]enkephalin from dynorphin I-S and the ontogeny of 
the opioid peptides and their receptors do display a degree of similarity. This is 
a possible indication of the importance of the conversion process within the 
c.n.s. 
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CHAPTER 7 
General Discussion 
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GENERAL DISCUSSION 
As with many other neuropeptides dynorphin I-S is rapidly inactivated by 
c.n.s. tissue [10,57,77,91,173]. This inactivation, especially the cleavage of the 
N-terminal tyrosine residue, creates problems when short dynalphin peptides 
are used to define the kappa receptor in ligand binding studies as the metabolic 
inactivation leads to an underestimation of the potency of the dynorphin peptide 
[28,84,130,133]. Inclusion of enzyme inhibitors, such as bestatin, captopril and 
thiorphan in the incubation medium results in the partial stabilization of the 
dynorphin 1-8 molecule against peptidase attack [48]. However, the enzyme 
inhibitors afford additional problems as they themselves interfere with binding 
studies to reduce the levels of bound peptide [108]. Lower incubation 
temperatures is an alternative strategy used to decrease enzymatic activity, 
however, lower temperatures not only slow the rate of metabolism but greatly 
lengthen the time required for ligands to reach equlibrium. 
The problem of metabolic inactivation is not confined to isolated receptor 
binding studies. Isolated tissues such as the mouse vas-deferens [108] and the 
MPLM of the guinea-pig also rapidly inactivate dynorphin I-S. This once again 
leads to an under estimation of the potency of dynorphin 1-8, as illustrated by 
the decrease in ICso of the octapeptide in the MPLM upon the addition of 
peptidase inhibitors. 
In addition to the inactivation of dynorphin I-S via the removal of the N-
terminal tyrosine residue, results presented in this thesis show that there is a 
direct cleavage of the LeuS-Arg6 bond within the octapeptide affording the 
pentapeptide [Leu]enkephalin. This process of producing [Leu]enkephalin is 
not a simple sequential attack on the C-terminal of dynorphin 1-8 because: 
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1.) The metabolites dynorphin 1-6 and dynorphin 1-7 fonn less than 2% of the 
recovered radioactivity and addition of the enzyme inhibitor cocktail does not 
increase the level of either peptide. 
2.) The level of recoverable [Leu]enkephalin is increased upon the addition of 
the cocktail of enzyme inhibitors, indicating that the enzyme responsible for the 
production of the [Leu]enkephalin is unaffected by such peptidase inhibitors 
and that any [Leu]enkephalin fonned is itself protected from metabolism by the 
inhibitor cocktail. 
3.) Site directed inhibitors of the enzyme EC 3.4.24.15 substantially reduce the 
level of [Leu]enkephalin produced from dynorphin 1-8 without affecting any 
other metabolite. 
If one imposes the criteria that only a direct cleavage of the Leu5_Arg6 bond 
within dynorphin 1-8 can be viewed as a conversion process then the kappa 
preferring dynorphin 1-8 is converted to the delta/mu preferring 
[Leu]enkephalin. This problem is further exacerbated in the presence of enzyme 
inhibitors which, in addition to protecting the dynorphin 1-8 stabilize any 
[Leu]enkephalin fonned, thereby amplifying the interference of the delta/mu 
preferring pentapeptide. This will be of great importance when one is using 
dynorphin 1-8, in the presence of enzyme inhibitors, to define a kappa receptor 
population in a tissue that contains a heterogenous population of opioid 
receptors. 
This conversion process appears to take place in vivo. Zamir and colleagues 
observed adynorphinergic pathway for the production of [Leu]enkephalin in 
the substantia nigra of the rat [176]. It is worth noteing that levels of [Met] and 
[Leu]enkephalin are altered independently in nigral areas of Parkins on diseased 
83 
brains, a process suggestive of a dynorphinergic pathway of [Leu]enkephalin 
production in man [152]. In Parkinson diseased brains [Leu] and 
[Met]enkephalin levels decrease in both the internal and external portions of the 
globus pallidus and the putamen. However in the substantia nigra only 
[Met]enkephalin levels are decreased with no corresponding change in 
[Leu]enkephalin or dynorphin 1-17. These observations suggest that in the 
putamen and pallidus dynorphin neurones are not the major source of 
[Leu]enkephalin and only proenkephalin A neurones are affected by Parkinsons 
Disease. Alternatively in these areas proenkephalin A could be located within 
doparninergic neurones and the observed decrease in proenkephalin A products 
is secondary to the atrophy of dopamine containing neurones associated with 
Parkinsons Disease [152]. 
The observation of the wide distribution of the enzyme(s) capable of cleaving 
the Leu5-Arg6 bond and their availability at very early stages in development 
suggests an important physiological role for this conversion. This role would, 
however vary throughout the c.n.s .. Thus, although there is sufficient evidence 
to view the production of [Leu ]enkephalin from dynorphin 1-8 as a conversion 
process ego in areas containing a mixed population of opioid receptors, this 
would not be an appropriate view in areas containing a homogenous kappa 
receptor population. In such areas the production of [Leu]enkephalin would 
best be regarded, within the current boundaries of evidence, as a metabolic 
inactivation since [Leu]enkephalin has a very low, if any, affmity at kappa 
receptors [96, 177]. It would be of special interest if this process was under 
some form of variable control [78]. For example there is a clear association 
between stress and the release of opioid pep tides [2]. 
However, before it will be possible to address fully the question of 
physiological releva~ce of the production of [Leu]enkephalin from dyprphin 1-
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S, the controversy surrounding the nature and number of enzymes involved in 
the conversion process must be answered. More work remains to be done in 
this area. The precise location of the enzyme is required, especially with regard 
to the synaptic junction. It is important to know whether the enzyme has a 
specific location for example, in the synaptic cleft or within the terminals 
themselves. It is interesting to note that in the rat pituitary [Met]enkephalin 
levels are maintained under opioid inhibition [46]. Administration of the opioid 
antagonist naloxone causes a significant increase in the level of [Met]enkephalin 
found in both the neurointermediate and anterior lobes of the pituitary. However 
similar treatment with the mu preferring agonist 
[D-Ala2,MePhe4,Met(0)501]enkephalin failed to affect [Met]eJephalin levels. 
The increase in [Met]enkephalin levels could result from a increase in synthesis 
or decrease in release, as in vitro naloxone has been shown to decrease the 
release of [Met]enkephalin from rat striatum [134]. This may be tha first 
indication of an opioid autoregulation system It is interesting to speculate the 
role of metabolism of the kappa preferring dynorphin I-S to the mu/delta 
preferring [Leu]enkephalin in such a system. 
As discussed in Chapter 4 controversy remains regarding the exact nature of the 
enzyme involved in the hydrolysis of the Leu5-Arg6 bond within dynorphin I-
S. The two candidate enzymes one a thiol protease namely endo-oligopeptidase 
A [18] the other a metalloendopeptidase classified E.C. 3.4.24.15 [119] both 
appear to be able to produce [Leu]enkephalin from dynorphin I-S. However 
evidence has been published suggesting that the metalloendopeptidase E.C. 
3.4.24.15 is devoid of the ability to hydrolyse the Leu5_Arg6 bond of 
dynorphin I-S [154]. Results described in this thesis are also inconclusive with 
regard to the type of enzyme involved. The metabolism displays characteristics 
both of a metalloendopeptidase and a thiolprotease. it is therefore possible that a 
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mixture of the two enzymes is responsible for the metabolism described in this 
thesis. 
Perhaps the most important observation contained within this thesis is that 
extreme care must be taken when using labile peptides to define or characterise 
any given receptor type, especially when enzyme inhibitors are used in an 
attempt to stabilize the peptide. This observation cannot be confmed to the 
opioid system. In addition the results presented in Chapter 5 demonstrate that, 
when correctly and sufficently stabilized, dynorphin 1-8 is a potent and very 
selective peptide for kappa over mu opioid recptors, its selectivity for the kappa 
opioid receptor being comparable to that displayed by dynorphin 1-17 and the 
synthetic ligand U69 593. 
FUTURE WORK 
Future work must consider the physiological role for this enzymatic conversion, 
for example does the metabolism form the basis of an autoinhibition process as 
discussed above. The question of the exact nature of the enzyme responsible for 
the metabolism remains to be resolved. This resolution is necessary to 
determine whether the process is a specific or a non-specific hydrolysis. 
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APPENDIX 
This appendix contains the tabulated data from which the graphs in Chapters 3-6 
were constructed. 
The fIrst number of each table refers to the chapter in which the respective graph 
can be found. 
For abbreviations see front of thesis. 
Incubation Time (min) % Recovered Radioactivity 
N-Tenninal [Leu]Enkephalin 
0 0.8 ± 0.4 0.3 ± 0.2 
0.5 12.0 ± 3.6 6.0 ± 1.4 
1 18.8±4.1 9.9 ± 2.5 
2 28.3 ± 3.3 16.8 ± 3.4 
5 47.6 ± 4.6 22.5 ± 3.5 
10 63.5 ± 3.5 21.6 ± 3.3 
20 81.4 ± 4.1 11.0 ± 3.3 
Table 3.1 Time course of metabolism of [3H]dynorphin 1-8 by slices ofrat spinal cord 
n=6 
Dynorphin 1-8 
98.3 ± 0.9 
79.7 ± 5.2 
68.8 ± 5.1 
50.3 ± 5.1 
24.5 ± 5.2 
7.9 ± 2.3 
2.4 ± 1.3 
Incubation Time (min) % Recovered Radioactivity 
N-Terminal [Leu]Enkephalin Dynorphin 1-8 
0 0.0 ± 0.0 5.83 ± 3.9 91.7 ± 4.2 
0.5 1.2 ± 1.0 6.7 ± 2.3 90.7 ± 3.8 
1 1.2 ± 0.6 14.2 ± 5.0 84.0 ± 6.9 
2 2.4 ± 1.1 20.7 ± 5.9 70.3± 9.8 
5 4.8 ± 1.6 34.6 ± 6.5 50.7 ± 9.5 
10 5.9 ± 2.2 60.5 ± 2.2 16.2 ± 4.2 
Table 3.2 Time course of metabolism of [3H]dynorphin 1-8 by rat spinal cord in the presence of 10IlM bestatin; 10IlM 
captopril; O.3IlM thiorphan and 2mM leucyl-leucine. 
n=5 
Tissue % Recovered Radioactivity 
N-terrninal [Leu]Enkephalin Dynorphin 1-8 
Cortex 5.3 ± 1.0 67.0 ± 3.6 17.8 ±5.0 
Striatum 4.6 ± 0.8 52.4 ± 3.0 33.5 ± 2.2 
Hypothalamus 4.6 ± 0.6 45.7 ± 6.7 42.2 ± 6.2 
Hippocampus 5.0 ± 1.0 57.4 ± 4.0 30.3 ± 5.3 
Medulla 6.0 ± 2.6 49.0 ± 1.1 37.7 ± 3.2 
Cerebellum 15.5 ± 2.9 57.8 ± 3.4 17.3 ± 1.3 
Spinal Cord 5.9 ± 1.0 50.25 ± 6.1 32.2 ± 8.4 
Table 3.3 Metabolism of [3H]dynorphin 1-8 by various areas of the rat C.n.S. in the presence of 
the inhibitor cocktail (bestatin lOJlM; captopril IOJlM and thiorphan O.3JlM) following a 1000il 
incubation period. 
n=4 
Metabolite % Recovered 
Radioactivity 
N-terminal 49.5 ± 3.2 
[Leu]Enkephalin 35.2 ± 11.7 
Dynorphin 1-8 6.3 ± 2.1 
Table 3.4 Metabolism of [3H]dynorphin 1-8 by 
guinea-pig cerebellum following a 10min 
incubationperiod. 
n=9 
Metabolite % Recovered 
Radioactivity 
N-terminal 22.2 ± 2.0 
[Leu]Enkephalin 55.9 ± 2.4 
Dynorphin 1-8 + 
Inhibitor Cocktail 8.5 ± 1.3 
Table 3.5 Metabolism of [3H]dynorphin 1-8 by ... 
guinea-pig cerebellum in the presence of the 
inhibitor cocktail (bestatin 101lM. captopril 
10IlM and thiorphan 0.3IlM) following a 10 min 
incubation period. 
n=9 
Incubation Time (min) % Recovered Radioactivity 
N-terminal [Leu ]Enkephalin Dynorphin 1-8 
0 3.1 ± 0.2 0.4 ± 0.4 96.3 ± 0.5 
2.5 40.1 ± 2.3 - 9.7 ± 0.4 44.9 ± 4.6 
5 55.3 ± 5.0 12.7 ± 0.6 25.1 ± 8.4 
10 80.5 ± 4.2 8.2 ± 1.2 7.0 ± 3.0 
20 96.3 ± 1.5 3.3 ± 0.3 1.3 ± 0.4 
Table 3.6 Time course of metabolism of [3H]dynorphin 1-8 by slices of guinea-pig myenteric plexus longitudinal muscle. 
n=3 
Incubation Time (min) % Recovered Radioactivity 
N-Terminal [Leu]Enkephalin Dynorphin 1-8 
0 1.2 ± 0.3 0.5 ± 0.5 98.3 ± 0.4 
2.5 4.7 ± 0.6 12.9 ± 3.8 79.6 ± 4.0 
5 7.4 ± 0.8 24.4 ± 4.2 57.7 ± 5.7 . 
10 14.9 ± 1.6 34.2 ± 1.2 38.2 ± 8.0 
20 31.4 ± 4.9 41.7 ± 1.0 14.0 ± 3.8. 
Table 3.7 Time course of the metabolism of [3H]dynorphin 1-8 by slices of guinea-pig myenteric plexus longitudinal muscle in the 
presence of: bestatin, lOflM, captopril, IOflM and thiorphan, 0.3 flM. 
n=3 
Competing Drug 
[Leu]Enkephalin 
[Met]EnkephaIin 
Dynorphin 1-6 
Dynorphin 1-7 
Dynorphin 1-8 
[Met]Enkephalyl-
Arg6-G1y7 -Leu8 
Dynorphin 1-9 
Dynorphin 1-13 
Dynorphin 1-17 
B-Endorphin 
DAGOL 
DADLE 
Morphine 
% Inhibition of eH][Leu]EnkephaIin 
Production 
5.56 ± 4.56 
2.17 ± 2.17 
5.92 ± 4.09 
22.8 ± 9.84-1.< 
52.91 ± 5.54* 
52.1 ± 2.50 " 
51.0 ± 5.62 !I'-
* .. 88.8 ± 3.52 
8.6 ± 4.3 
N.E. 
N.E. 
N.E. 
N.E. 
% Increase in Recoverable 
[3H]Dynorphin 
1.30 ±1.30 
0.53 ± 0.53 
15.45 ± 6.92 
35.10 ± 17.56-{-
84.48 ± 6.15 '* 
96.64 ± 3.81 *" 
82.7 ± 6.12 "*" 
158.6 ± 14.3 Ni" 
1.6 ± 1.6 
N.E. 
N.E. 
N.E. 
N.E. 
Table 4.1 The effect of various pep tides and drugs on the ability ofrat spinal cord slices to produce [3H][Leu]enkephalin from 
[3H]dynorphin 1-8. 
N.E. = No Effect 
n=4 
.,. p <..0 -05 c.1' h:, co;'\ h'oL 
of" ~ Co'OI op m Cof\rrol 
5hlcla.rh,. I:. -l:QD~ 
Inhibitor Concentration (mM) % Inhibition of [Leu ]Enkephalin Production 
TRIS Krebs/Hepes 
PMSF 1 6.85 ± 4.4' N.T. 
DIT 2 42.22 ± 17.2"" 46.1b 
NEM 1 45.83 ± 13.7 ~ 56.45 ± 11.8" 
Il.CMB 0.2 92.2 ± 2.17 l'''' 93.2 ± 3.831" 
Q-Phen 1 28.16 ± 8.6* 60.49 ± 30.3 't: 
EDTA 1 0.0 ± 0.0 0.0 ± 0.0 
Table 4.2 Inhibition of [3H] [Leu]enkephalin production from [3H]dynorphin 1-8 following a 10 min incubation period, by rat spinal cord 
tissue preincubated with the inhibitor cocktail (bestatin lOf.lM; captoprill0f.lM and thiorphan O.3f.lM) and a variety of chemical inhibitors, in 
either TRIS buffer or Krebs buffered with Hepes (for abbreviations see text). 
n = 3 except where indicated. 
a, n =6 
b, n =2 
N.T. '= Not Tested 
~ ~c.o·o~ '1' ~~'rroL 
~"'PL.o·O\ 'f \-0 ClW\\1eL 
sl\klQM\:o l.tAd:-
Agonist 
U50488H 
U69593 
Dynorphin 1-17 
DAGOL 
[Leu]Enkephalin + 
Inhibitor cocktail 
Dynorphin 1-8 
Dynorphin 1-8 + 
Inhibitor cocktail 
Dynorphin 1-8 + 
Inhibitor cocktail + 
N-(R,S)-ethyl 
Dynorphin 1-8 + 
Inhibitor cocktail+ 
N-(R,S)-propyl 
IC50(nM) 
1.5 ± 0.14 
2.8 ± 0.47 
0.32 ± 0.02 
16.6 ± 3.75 
36.8 ± 7.0 
- 27.37 ± 3.7 
1.8 ± 0.34 
1.89 ± 0.72 
2.77 ± 0.22 
NaloxoneKe Slope n 
19.62 ± 1.4 S.D. 6 
31.4 ± 9.69 0.98 ± 0.08 4 
33.55 ± 1.02 1.07 ± 0.03 4 
2.09 ± 0.54 0.92.± 0.04 3 
1.63 ± 0.34 0.94 ± 0.03 8 
14.03 ± 2.4 0.92 ± 0.03 19 
3.01 ± 0.79 0.86 ± 0.08* 9 
14.31±2.1 S.D. 3 
37.2 ± 8.3 0.99 ± 0.09 5 
Table 5.1 Values ofICso, Ke against naloxone and Schild plot slopes for a variety ofligands in the guinea-pig myenteric plexus 
longitudinal muscle preparation. * value is significantly different from unity P<0.05 i'<\0-Y\V\ \N'v--i'c.NL\/ -L\. -_ 
n = number of observations 
S.D. = single dose method used to calculate Ke 
Agonist IC50 (nM) Ke (nM) Slope n 
U69593 2.22 ± 0.21 0.06 ± 0.01 1.07 ± 0.03 4 
DAGOL 23.14 ± 3.27 13.03 ± 1.91 1.04 ± 0.08 5 
Dynorphin 1-8 19.66 ± 4.2 0.17 ± 0.04 0.98 ± 0.08 4 
Dynorphin 1-8 + 
Inhibitor Cocktail 3.66 ± 0040 0.62 ± 0.Q7 1.07 ± 0.03 7 
Dynorphin 1-8 + 
Inhibitor Cocktail + 
N-(R,S)-phenyl 0.88 ± 0.16 0.098 ± 0.047 0.99 ± 0.12 4 
Table 5.2 IC50, Ke against nor-BNI and Schild plot slope values for various agonists on the guinea-pig myenteric plexus 
longitudinal muscle preparation. 
n = number of experimental observations 
Agonist ICso(nM) Ke (nM) Slope n 
U69 S93 2.S6 ± 0.62 85.8 ± 14.4 0.91 ± O.OS 4 
DAGOL 10.18 ± 2.S 3.S ± 1.2 0.91 ± O.OS 4 
Dynorphin 1-8 42.9 ± 11.0 76.9 ± 11.1 0.91 ± 0.03 4 
Dynorphin 1-8 + 
Inhibitor Cocktail 1.7 ± 0.3 31.4 ± 8.8 0.79 ± 0.01* 4 
Dynorphin 1-8 + 
Inhibitor Cocktail + 
N-(R,S)-propy1 2.8 ± 0.6 208.S ± 70.3 1.05 ± 0.05 4 
Table 5.3 ICso, Ke against M8008 and Schild plot slope values for various agonists on the guinea-pig myenteric plexus 
longitudial muscle preparation. 
n = number of experimental observations 
>I< = significantly different from unity P<O.OS (Mann-Whitney U test) 
Agonist ICso (nM) Dose Ratio n 
Before B-FNA AfterB-FNA (afterlbefore ) 
DAGOL 12.3 ± 1.7 263.4 ± 55.8 26.1 ± 7.5 12 
U50488H 1.73 ± 0.56 1.96 ± 0.43 1.08 ± 0.08 4 
[Leu]Enkephalin + 
Inhibitor Cocktail 33.0 551.5 15.9 2 
Dynorphin 1-8 18.56 ± 5.6 11.6 ± 2.5 0.61 ± 0.08 4 
Dynorphin 1-8 + 
Inhibitor Cocktail 1.08 ± 0.22 2.53 ± 0.23 2.57 ± 0.35 6 
Dynorphin 1-8 + 
Inhibitor Cocktail + 
N-(R,S)-phenyl 2.08 ± 0.13 1.75 ± 0.08 0.8 ± 0.05 3 
Table 5.4 The effect of B-BFNA (lOOnM for lhr) on the ICso values of a variety of opioid agonists.on the guinea-pig myenteric 
plexus longitudinal muscle 
n = number of experimental observations 
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